

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199856891 B2
(10) Patent No. 746595

(54) Title
IL-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders

(51)⁷ International Patent Classification(s)
C12N 015/12 C12N 015/11
A61K 038/17 C12Q 001/68
C07K 014/715 G01N 033/566
C12N 005/10 G01N 033/68

(21) Application No: **199856891**

(22) Application Date: **1997.12.02**

(87) WIPO No: **WO98/24904**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/032224	1996.12.02	US
NOT GIVEN	1997.12.01	US

(43) Publication Date : **1998.06.29**

(43) Publication Journal Date : **1998.08.20**

(44) Accepted Journal Date : **2002.05.02**

(71) Applicant(s)
Genaera Corporation

(72) Inventor(s)
Roy Clifford Levitt; Luigi Grasso; Nicholas C. Nicolaides; Kenneth J. Holroyd

(74) Agent/Attorney
F B RICE and CO,605 Darling Street,BALMAIN NSW 2041

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/715, C12Q 1/68, G01N 33/566, 33/68, A61K 38/17, C12N 5/10, 15/11		A2	(11) International Publication Number: WO 98/24904
			(43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/21992		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 2 December 1997 (02.12.97)			
(30) Priority Data: 60/032,224 2 December 1996 (02.12.96) US Not furnished 1 December 1997 (01.12.97) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: <i>Genacera Corporation</i> MAGNIN PHARMACEUTICALS INC. [US/US]; 5110 Campus Drive, Plymouth Meeting, PA 19462 (US).			
(72) Inventors: LEVITT, Roy, Clifford; 660 Marsten Green Court, Ambler, PA 19002 (US). GRASSO, Luigi; 136 North Bread Street, Philadelphia, PA 19106 (US). NICOLAIDES, Nicholas, C.; 4 Cider Mill Court, Boothwyn, PA 19061 (US). HOLROYD, Kenneth, J.; 112 Mennonite Road, Collegeville, PA 19426 (US).			
(74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).			

(54) Title: IL-9 RECEPTOR VARIANTS, USEFUL IN TREATING AND DIAGNOSING ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS

[illegible]

(57) Abstract

This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor (2). One embodiment of the invention is a variant of AAF2, wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

IL-9 RECEPTOR VARIANTS, USEFUL IN TREATING AND DIAGNOSING
ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS

CROSS-REFERENCE TO RELATED APPLICATION

This application is related to U.S. Provisional Application Serial No. 60/032,224 which was filed December 2, 1996, and is incorporated by reference. It is also related to the subject matter of U.S. Patent Application Serial Nos. 08/697,419,
5 08/697,360, 08/697,473, 08/697,472, 08/697,471, 08/702,105, 08/702,110, 08/702,168 and 08/697,440 all of which were filed on August 23, 1996, and 08/874,503 filed on June 13, 1997, and are herein incorporated by reference.

FIELD OF THE INVENTION

10 This invention describes biologic variability in the IL-9 receptor (Asthma Associated Factor 2) (SEQ ID NO1) and relates these sequence variants to susceptibility to asthma, atopic allergy, and related disorders. This invention also teaches methods that utilize these IL-9 receptor sequence variants for the diagnosis of susceptibility or resistance to asthma and atopic allergy. In
15 addition, methods are described that use variant IL-9 receptors in the development of pharmaceuticals for asthma which depend on the regulation of IL-9 activity.

BACKGROUND OF THE INVENTION

20 Inflammation is a complex process in which the body's defense system combats foreign entities. While the battle against foreign entities may be necessary for the body's survival, some defense systems improperly respond to foreign entities, even innocuous ones, as dangerous and thereby damage surrounding tissue in the ensuing battle.

25 Atopic allergy is a disorder where genetic background dictates the response to environmental stimuli. The disorder is generally characterized by an

increased ability of lymphocytes to produce IgE antibodies in response to ubiquitous antigens. Activation of the immune system by these antigens also leads to allergic inflammation which may occur after their ingestion, penetration through the skin, or after inhalation. When this immune activation occurs and pulmonary inflammation ensues, this disorder is broadly characterized as asthma. Certain cells are important in this inflammatory reaction in the airways and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells/basophils that store inflammatory mediators and bind IgE, and eosinophils that release additional mediators. These inflammatory cells accumulate at the site of allergic inflammation, and the toxic products they release contribute to the tissue destruction related to the disorder.

While asthma is generally defined as an inflammatory disorder of the airways, clinical symptoms arise from intermittent airflow obstruction. It is a chronic, disabling disorder that appears to be increasing in prevalence and severity.¹ It is estimated that 30-40% of the population suffer with atopic allergy, and 15% of children and 5% of adults in the population suffer from asthma.¹ Thus, an enormous burden is placed on our health-care resources in the treatment of these disorders.

Both the diagnosis and treatment of asthma and related disorders are problematic.¹ In particular, the assessment of inflamed lung tissue is often difficult, and frequently the cause of the inflammation cannot be determined. Although atopic asthma is an ecogenetic disorder, knowledge about the particular variant genes has only recently been discovered. Methods to detect these genetic variations and their role in inflammation, diagnosis and prognosis remain to be determined. What is needed in the art is the development of technology to expedite the diagnosis of atopic asthma that specifically relates to variation in genes responsible for susceptibility/resistance to this atopic disease.

Current treatments suffer their own set of disadvantages. The main therapeutic agents, β -agonists, reduce the symptoms, i.e., transiently improve pulmonary functions, but do not affect the underlying inflammation so that lung tissue remains in jeopardy. In addition, constant use of β -agonists results in desensitization which reduces their efficacy and safety.² The agents that can diminish the underlying inflammation, the anti-inflammatory steroids, have their own known list of side effects that range from immunosuppression to bone loss.²

Because of the problems associated with conventional therapies, alternative treatment strategies have been evaluated.³⁸⁻³⁹ Glycophorin A,³⁷ cyclosporin,³⁸ and a nona peptide fragment of IL-2,³⁶ all inhibit interleukin-2 dependent T lymphocyte proliferation.²⁸ They are, however, known to have many other effects.² For example, cyclosporin is used as an immunosuppressant after organ transplantation. While these agents may represent alternatives to steroids in the treatment of asthmatics,³⁶⁻³⁹ they inhibit interleukin-2 dependent T lymphocyte proliferation and potentially critical immune functions associated with homeostasis. What is needed in the art is technology to expedite the development of therapeutics that are specifically designed to treat the cause, and not the symptoms, of atopic asthma. These therapies represent the most likely way to avoid toxicity associated with nonspecific treatment. The therapies would selectively target a pathway, which is downstream from immune functions, such as IL-2 mediated T lymphocyte activation, that is necessary for the development of asthma and which would explain the episodic nature of the disorder and its close association with allergy. Nature demonstrates that a pathway is the appropriate target for asthma therapy when biologic variability normally exists in the pathway and individuals demonstrating the variability are not immunocompromised or ill except for their symptoms of atopic asthma.

Because of the difficulties related to the diagnosis and treatment of atopic allergies including asthma, the complex pathophysiology of these disorders is

under intensive study. While these disorders are heterogeneous and may be difficult to define because they can take many forms, certain features are found in common among asthmatics. Examples of such features include abnormal skin test response to allergen challenge, eosinophilia in the lung, bronchial hyperresponsiveness (BHR), bronchodilator reversibility, and airflow obstruction.³⁻¹⁰ These expressions of asthma related traits may be studied by quantitative or qualitative measures.

In many cases, elevated IgE levels are correlated with BHR, a heightened bronchoconstrictor response to a variety of stimuli.^{4,6,8,9} BHR is believed to reflect the presence of airway inflammation,^{6,8} and is considered a risk factor for asthma.¹¹⁻¹² BHR is accompanied by bronchial inflammation, including eosinophil infiltration into the lung and an allergic diathesis in asthmatic individuals.^{6,8,13-18}

A number of studies document a heritable component to atopic asthma.^{4,10} Family studies, however, have been difficult to interpret since these disorders are significantly influenced by age and gender, as well as many environmental factors such as allergens, viral infections, and pollutants.¹⁹⁻²¹ Moreover, because there is no known biochemical defect associated with susceptibility to these disorders, the mutant genes and their abnormal gene products can only be recognized by the anomalous phenotypes they produce.

The functions of IL-9 and the IL-9 receptor (the IL-9 pathway) now extend well beyond those originally recognized. While the IL-9 pathway serves as a stimulator of T cell growth, this cytokine is also known to mediate the growth of erythroid progenitors, B cells, mast cells, and fetal thymocytes.^{22,23} The IL-9 pathway acts synergistically with IL-3 in causing mast cell activation and proliferation.²⁴ The IL-9 pathway also potentiates the IL-4 induced production of IgE, IgG, and IgM by normal human B lymphocytes,²⁵ and the IL-4 induced release of IgE and IgG by murine B lymphocytes.²⁶ A role for the IL-9 pathway in the mucosal inflammatory response to parasitic infection has also been demonstrated.^{27,28}

Nevertheless, it is not known how the sequence of the IL-9 receptor specifically correlates with atopic asthma and bronchial hyperresponsiveness. It is known that IL-9 binds to a specific receptor expressed on the surface of target cells.^{23,29,30} The receptor actually consists of two protein chains: one protein chain, known as the IL-9 receptor, binds specifically with IL-9; the other protein chain is shared in common with the IL-2 receptor.²³ In addition, a cDNA encoding the human IL-9 receptor has been cloned and sequenced.^{23,29,30} This cDNA codes for a 522 amino acid protein which exhibits significant homology to the murine IL-9 receptor. The extracellular region of the receptor is highly conserved, with 67% homology existing between the murine and human proteins. The cytoplasmic region of the receptor is less highly conserved. The human cytoplasmic domain is much larger than the corresponding region of the murine receptor.²³

The IL-9 receptor gene has also been characterized.³⁰ It is thought to exist as a single copy in the mouse genome and is composed of nine exons and eight introns.³⁰ The human genome contains at least four IL-9 receptor pseudogenes. The human IL-9 receptor gene has been mapped to the 320 kb subtelomeric region of the sex chromosomes X and Y.²³

In spite of these studies, no variants of the IL-9 receptor gene have been discovered. There is, therefore, a specific need for genetic information on atopic allergy, asthma, bronchial hyperresponsiveness, and for elucidation of the role of IL-9 receptor in the etiology of these disorders. This information can be used to diagnose atopic allergy and related disorders using methods that identify genetic variants of this gene that are associated with these disorders. Furthermore, there is a need for methods utilizing the IL-9 receptor variants to develop therapeutics to treat these disorders.



Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

SUMMARY OF THE INVENTION

Applicants have discovered natural variants of the human IL-9 receptor (also known as Asthma Associated Factor 2 or AAF2) and have linked these

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201

variants to the pathogenesis of asthma and related disorders. These discoveries have led to the development of diagnostic methods, and methods to discover pharmaceuticals for the treatment of therapeutics for atopic asthma. In addition, applicants have determined that the IL-9 receptor is critical to a number of antigen-induced responses in mice, including bronchial hyperresponsiveness, eosinophilia and elevated cell counts in bronchial lavage, and elevated serum total IgE. These findings typify atopic asthma and the associated allergic inflammation.

Furthermore, applicants have determined that a G to A nucleic acid variant occurs at position 1273 of the cDNA (SEQ ID NO 2) which produces the predicted amino acid substitution of a histidine for an arginine at codon 344 of the human IL-9 receptor precursor protein. When the arginine residue occurs in both alleles in one individual, it is associated with less evidence of atopic asthma. Thus, applicants have identified the existence of a non-asthmatic phenotype characterized by arginine at codon 344 when it occurs in both IL-9 receptor gene products in one individual. As an additional significant corollary, applicants have identified the existence of susceptibility to an asthmatic, atopic phenotype characterized by a histidine at codon 344. Thus, the invention includes purified and isolated DNA molecules having such a sequence as well as the proteins encoded by such DNA.

Applicants have also determined that a splice variant of the IL-9R exists wherein the glutamine residue at position 173 of the IL-9R precursor protein has been deleted (SEQ ID NO 3) (Figure 5). Applicants have further shown that this variant is not able to transcribe a signal through the Jak-Stat pathway (Figure 15) and is unable to induce cellular proliferation upon stimulation with IL-9 (Figure 16); therefore, individuals with this allele would be less susceptible to atopic asthma and related disorders.

Applicants have further determined that a variant of the IL-9R genomic DNA exists wherein nt-213, a thymine residue in intron 5 (213 nt upstream from exon 6), has been converted to a cytosine nucleotide. It is likely that such a

variation can cause an increase in the frequency of the splice variant which removes the glutamine residue at the start of exon 6.

In addition, applicants have discovered a variant of IL-9R wherein exon 8 has been deleted (SEQ ID NO 4) which results in a change in reading frame and a premature stop codon in exon 9. Such a variant would most likely be prevented from transmitting a signal through the Jak-Stat pathway and, therefore, individuals with this allele would also be less susceptible to atopic asthma and related disorders.

The biological activity of IL-9 results from its binding to the IL-9 receptor and the consequent propagation of a regulatory signal in specific cells; therefore, IL-9 functions can be interrupted by the interaction of IL-9 antagonists with IL-9 or its receptor. Down regulation, i.e., reduction of the functions controlled by IL-9, is achieved in a number of ways. Administering antagonists that can interrupt the binding of IL-9 to its receptor is one key mechanism, and such antagonists are within the claimed invention. Examples include administration of polypeptide products encoded by the DNA sequences of a naturally occurring soluble form of the IL-9 receptor, wherein the DNA sequences code for a polypeptide comprising exons 2 and 3 (SEQ ID NO 5). Two other variations can produce soluble forms of the IL-9R receptor which comprise exons 2, 3 and 4 and in one case four amino acids from a different reading frame in exon 5 (SEQ ID NO 6) (Figure 6) and in the other case there are 27 amino acids from a different reading frame in exon 5 (SEQ ID NO 7) (Figure 7).

Methods to identify agonists and antagonists of the IL-9 receptor pathway can be identified by assessing receptor-ligand interactions which are well described in the literature. These methods can be adapted to high throughput automated assays that facilitate chemical screenings and potential therapeutic identification. Agonists are recognized by identifying a specific interaction with the IL-9 receptor. Loss of binding for a putative ligand which is labeled when a 100- to 1000-fold excess of unlabeled ligand is used is generally accepted as

evidence of specific receptor binding. Many labels and detection schemes can be used during these experiments. A similar loss of binding when increasing concentrations of test compound are added to a known ligand and receptor is also evidence for an antagonist.

5 Knowledge of the variant receptors provides the means to construct expression vectors that can be used to make soluble receptor for receptor binding assays. Mutagenesis of these soluble receptors can be used to determine which amino acid residues are critical to bind ligand and aid in the structure-based design of antagonists.

10 Cells lacking human IL-9 receptor can be transiently or stably transfected with expression vectors containing a variant receptor and used to assay for IL-9 pathway activity. These activities may be cellular proliferation, or prevention of apoptosis which have both been ascribed to the IL-9 pathway. These cells can be used to identify receptor agonists and antagonists as described above.

15 The methods discussed above represent various effective methods utilizing the variant forms of IL-9 receptor to develop therapeutics for atopic asthma and other related disorders.

A number of techniques have been described that may be used to diagnose atopic asthma that recognize single nucleotide variants in the IL-9 receptor including DNA sequencing, restriction fragment length polymorphisms (RFLPs), allele specific oligonucleotide analyses (ASO), ligation chain reaction (LCR), chemical cleavage, and single stranded conformational polymorphism analyses (SSCP). A skilled artisan will recognize that the use of one or more of these techniques, as well as others in the literature, may be used to detect one or more variations in the IL-9 receptor gene or mRNA transcript and are within the scope of the present invention.

25 Still other techniques may be used to detect amino acid variants in the IL-9 receptor including ELISAs, immunoprecipitations, Westerns, and immunoblotting. Thus, polyclonal and monoclonal antibodies which recognize specifically the structure of the various forms of the IL-9 receptor are also

30

within the scope of this invention and are useful diagnostic methods for describing susceptibility or resistance to atopic asthma and related disorders.

The methods discussed above represent various effective methods for diagnosing atopic asthma and other related disorders.

5 Thus, applicants have provided methods that use the IL-9 receptor to identify antagonists that are capable of regulating the interaction between IL-9 and its receptor. More specifically, applicants provide a method for assaying the functions of the IL-9 receptor to identify compounds or agents that may be administered in an amount sufficient to down-regulate either the expression or
10 functions of the IL-9 pathway.

Having identified the role of the IL-9 pathway in atopic allergy, bronchial hyperresponsiveness and asthma, applicants also provide a method for the diagnosis of susceptibility and resistance to atopic allergy, asthma, and related disorders.

15 The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principle of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

20 **Figure 1:** Schematic representation of the human IL receptor cDNA. Boxes depict exon 2 to 9 encompassing the coding region (relative size in scale, except the 3' untranslated part of exon 9, outlined by dashed line).

Transmembrane region is encoded by exon 7, intracellular domain by exon 8 and 9, and the extracellular by exon 2 to 6. Arrows indicate polymorphisms or aberrant splices affecting partial sequence of the exon; a) deletion of the first 5 or 29 nucleotides in exon 5; b) deletion of the first 3 nucleotides in exon 6
25 (codon 173); c) arg/gly polymorphism at codon 310; d) arg/his polymorphism at codon 344; e) polymorphism at codon 410+n consisting of either 8 or 9 serines; *) complete deletion of exon 3, 4 or 8.

Figure 2: Translated cDNA sequence of the wild type IL-9R precursor protein with Arg allele at codon 344 (nucleotides 1272-1274) and the 8 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 3: Translated cDNA sequence of the IL-9R precursor protein with the His allele at codon 344 (nucleotides 1272-1274) and the 9 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 4: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 8 causing a frame shift in exon 9, the production of 11 non-wild type amino acids and a premature stop codon.

Figure 5: Translated cDNA sequence of IL-9R precursor protein with the deletion of Glutamine at codon 173.

Figure 6: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 27 non-wild type amino acids.

Figure 7: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 4 non-wild type amino acids.

Figure 8: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 4 producing a stop codon as the first codon of exon 5.

Figure 9: Table showing the association between the IL-9 receptor genotype and atopic allergy. The Arg/Arg individuals are homozygous for the Arg allele with the 8 Ser/4 Asn repeats. The Arg/His individuals are heterozygous for the Arg allele with the 8 Ser/4 Asn repeats and the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The His/His individuals are homozygous for the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The Arg/Arg individuals are protected from atopic allergy. The Arg/His and His/His individuals are susceptible to atopic allergy ($P = 0.002$).

Figure 10: Map of the expression construct of the IL-9 receptor.

Figure 11: Western blot of recombinant IL-9 receptor proteins (left: Arg allele with the 8 Ser/4 Asn repeats; right: His allele with the 9 Ser/4 Asn repeats) using C terminal antibody probe in TK⁻ transfected cell line.

Figure 12: Expression of human IL-9 receptor variants in TS1 cells showing differential mobility between the Arg 344 variant with 8 Ser/4 Asn repeats (GR8) and His 344 variant with 9 ser/4 Asn repeats (GH9). A mobility shift is seen demonstrating differential post-translational modification of these two variant form of the IL-9 receptor.

Figure 13: XY specific amplimers for specific amplification of the IL-9 receptor gene. Pseudogenes on chromosomes 9, 10, 16, or 18 are not amplified by PCR. (M is mouse DNA, H is human DNA, and C is hamster DNA.)

Figure 14: Immunoreactivity of an anti-human IL-9 receptor neutralizing antibody with wild type and Delta-Q receptors. Panel A): COS7 cells were transiently transfected with the LXSXN vector alone (A and B), wild type IL-9R (C and D), Wild type IL-9R with 9 Ser residues starting with codon 410 (E and F), Δ -Q 173 variant (G and H) and Δ -Q 173 with 9 Ser residues starting at codon 410 (I and J) and sequentially incubated with MAB290 and anti-mouse IgG Texas Red-conjugated antibody (B,D,F,H and J) as described (Example 8). DAPI staining (A,C,E,G and I) was included to visualize every cell in the photographed field. Panel B): as in A) except that cells were first fixed/permeabilized and then incubated with a C-terminal specific antibody (sc698) followed by incubation with anti-rabbit IgG Texas Red-conjugated antibody. Bar = 10 microns.

Figure 15: Activation of members of Jak, Stat, and Irs families via different variants of the human IL-9 receptor. TS1 cells expressing either GH9, Δ QGR8, or Δ QGH9 were starved for 6 hours and then treated for 5 minutes without cytokine (-), with murine IL-9 (m), or with human IL-9 (h). Cell extracts were immunoprecipitated with various antibodies specific for different members of Jak, Stat and Irs families. Immunoblots were first reacted with an

anti-phosphotyrosine antibody to detect only tyrosine-phosphorylated proteins and then stripped and reprobed with the same antibody used to immunoprecipitate each protein. GH9, Δ QGR8, Δ QGH9 are as indicated in Figure 16.

Figure 16: Proliferation of TS1 cells expressing different forms of human IL-9 receptor. Cells were seeded in quadruplicate in 96-well plates (1000/well) and treated without cytokine or with murine or human IL-9 (5 ng/ml). A colorimetric assay was performed 7 days later to determine cell number, and the ratio between treated/untreated cells (% control) was calculated to assess growth rate. LxSN = cells transfected with the empty vector; GR8 is wild type IL-9R; GH9 is the His 344 variant with 9 Ser residues starting at codon 410; Δ QGR8 and Δ QGH9 are the Δ Q173 variants on the wild type and the His 344 + 9 - Ser background, respectively.

Figure 17: Genomic DNA sequence of intron 5 of the IL-9R with a variation at nucleic acid 213 nt upstream from exon 6 where a T residue is changed to a C residue as indicated by the arrow.

DETAILED DESCRIPTION OF THE INVENTION

Applicants have resolved the needs in the art by elucidating an IL-9 pathway, and compositions that affect that pathway, which may be used in the treatment, diagnosis, and development of methods to identify agents to prevent or treat atopic asthma and related disorders.

Asthma encompasses inflammatory disorders of the airways with reversible airflow obstruction. Atopic allergy refers to atopy, and related disorders including asthma, bronchial hyperresponsiveness (BHR), rhinitis, urticaria, allergic inflammatory disorders of the bowel, and various forms of eczema. Atopy is a hypersensitivity to environmental allergens expressed as the elevation of serum total IgE or abnormal skin test responses to allergens as compared to controls. BHR refers to bronchial hyperresponsiveness, a heightened bronchoconstrictor response to a variety of stimuli.

By analyzing the DNA of individuals that exhibit atopic allergy and asthma-related disorders, applicants have identified polymorphisms in the IL-9 receptor (IL-9R) gene that may correlate with the expression of asthma. The IL-9 receptor gene (also known as Asthma Associated Factor 2 or AAF2) refers to the genetic locus of interleukin-9 receptor, a cytokine receptor associated with a variety of functions involving the regulation of human myeloid and lymphoid systems. The human IL-9 receptor gene of the present invention is found in the subtelomeric region of the XY chromosomes.

By polymorphism, applicants mean a change in a specific DNA sequence, termed a "locus," from the prevailing sequence. In general, a locus is defined as polymorphic when artisans have identified two or more alleles encompassing that locus and the least common allele exists at a frequency of 1% or more.

Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), non-processed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., Oncogene, 9:1327-1332, 1994; Gruss, et al., Cancer Res., 52:1026-1031, 1992), applicants have designed specific amplimers. The specific primers were found to be authentic for IL-9R amplification with no amplification of the 4 pseudogenes. The primer sequences are shown in Example 2 and their specificity is demonstrated in Figure 13.

Applicants have also amplified, by RT-PCR, the entire coding region of the IL-9 receptor cDNA using RNA extracted from PBMCs (peripheral blood

mononuclear cells) purified from 50 donors. Fig. 1 illustrates the most frequent variations found in 50 individuals analyzed. Exon 3, 4, 5, 6 and 8 were affected by aberrant splicing events in samples where full-length cDNAs could also be cloned. Some transcripts showed complete deletion of exon 3, which causes a frameshift creating a stop codon after a stretch of 79 unrelated residues. In the case of deletion of exon 4, a frameshift is also generated and the first codon in exon 5 is converted to a stop codon. In some other cDNAs, exon 5 presented partial deletion of the first 5 or 29 nucleotides, both deletions leading to frameshifts resulting in early stop codons within exon 5. Hence, in all instances, the putative truncated protein would lack most of the extracellular domain as well as all the transmembrane and cytoplasmic domains. If secreted, these forms might function as soluble receptors. Finally, the first three nucleotides of exon 6, corresponding to codon 173, were frequently found spliced out, resulting in deletion of the glutamine at this codon with no other changes in the remaining protein sequence. This splice variant is possibly related to a variant found in intron 5 of the genomic DNA (SEQ ID NO 24) which would increase the frequency of the splice variant (Figure 17 and Example 12).

Applicants have also found allelic variations limited to the coding sequence of exon 9. Polymorphisms involving codon 310 and 410 have been previously disclosed.^{29, 30} (Kermouni, A., et al., Genomics, 371-382 (1995)). Codon 310 encodes for either arginine or glycine, depending on whether the first nucleotide at that codon is an adenine or a guanine, respectively. At codon 410 (from hereon termed "410+n") begins a stretch of either 8 or 9 AGC trinucleotides repeats which would be translated in 8 or 9 serines, respectively.

Applicants have found a new polymorphism at codon 344. Here, the second nucleotide is either adenine or guanine, the two possible residues encoded by this codon being histidine or arginine, respectively. Moreover, a correspondence between codon 344 and 410+n was observed wherein arginine at codon 344 is consistently found with 8 serines at codon 410+n and

histidine at codon 344 is found with 9 serines. The human IL-9 receptor cDNA originally cloned from a human megakaryoblastic leukemic cell line, Mo7e, presented 9 serines at codon 410+n and, unlike applicants' clones, an arginine at codon 344.²⁹ Another megakaryoblastic leukemic cell line UT-7 has
5 been reported to carry the same arginine/9-serines allele.³⁰ Applicants cloned 16 cDNAs from Mo7e cell line and found that 6 had 8 serines at codon 410+n and arginine at codon 344. The remaining ten clones presented the published sequence. Applicants also genotyped the human acute myelogenous leukemia cell line KG-1 and found that it was histidine/9-serines homozygous.

10 These DNA molecules and corresponding RNA are isolated using techniques that are standard in the art, such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985). By isolated, applicants mean that the DNA is free of at least some of the contaminants associated with the nucleic acid or polypeptides occurring in a
15 natural environment.

The invention also includes the proteins encoded by these nucleic acid sequences. The invention further includes fragments of the molecules. By fragments, applicants mean portions of the nucleic acid sequence that maintain the function of the full sequence. As would be known in the art,
20 fragments result from deletions, additions, substitutions and/or modifications.

The source of the IL-9 receptor variants of the invention is human. Alternatively, the DNA or fragment thereof may be synthesized using methods known in the art. It is also possible to produce the compound by genetic engineering techniques, by constructing DNA by any accepted technique;
25 cloning the DNA in an expression vehicle and transfecting the vehicle into a cell which will express the compound. See, for example, the methods set forth in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985).

30 The demonstration of variant IL-9 receptor sequences which may be associated with atopic allergy and an asthma-like phenotype, and others which

may be associated with the lack of an asthma-like phenotype, provides methods of diagnosing susceptibility to atopic asthma and related disorders. Certain variants can produce soluble receptors which can be used for treating these disorders.

5 A receptor is a soluble or membrane-bound component that recognizes and binds to molecules, and the IL-9 receptor of the invention is the component that recognizes and binds to IL-9. The functions of the IL-9 receptor consist of binding to IL-9 or an IL-9-like molecule and propagating its regulatory signal in specific cells.^{29,30,34,35} Human IL-9 has been shown to cause phosphorylation
10 of the IL-9 receptor itself and the activation of proteins of the Jak-Stat pathway, Jak1, Stat1, Stat3, Stat5, and Irs2, upon binding the human IL-9 receptor (Demoulin, J-B., et al., Molecular and Cellular Biology, p. 4710-4716, Sept. 1996). Applicants have examined whether IL-9R or its variants showed any bias in the activation of these proteins and extended the analysis to Jak3 and
15 Irs1. It was determined that all of the proteins of the pathway including Jak3 and Irs1 were phosphorylated by IL-9R activation. It was also determined that IL-9R variants with changes at codons 310, 344 and 410+n provided the same up-regulation as wild type IL-9R. Therefore, one aspect of the invention is therapeutics for the treatment of atopic asthma which inhibit interactions in the
20 Jak-Stat pathway.

Unlike the wild type receptor and the other tested variants, the Δ Q173 variant could not activate any proteins in the Jak-Stat pathway (Figure 15). In addition, the Δ Q173 variant could not support cellular proliferation upon IL-9 stimulation (Figure 16). Therefore, individuals who express the Δ Q173 variant
25 are less likely to be susceptible to atopic asthma and related disorders. One aspect of the invention, therefore, is therapeutics that increase the expression of the Δ Q173 splice variant for the treatment of atopic asthma and related disorders.

One diagnostic embodiment involves the recognition of variations in the DNA
30 sequence of the IL-9 receptor gene or transcript. One method involves the use

of a nucleic acid molecule (also known as a probe) having a sequence complementary to the IL-9 receptors of the invention under sufficient hybridizing conditions, as would be understood by those in the art. In one embodiment, the nucleic acid molecule will bind specifically to the codon for Arg344 of the mature IL-9 receptor protein, or to His344, and in another embodiment will bind to both Arg344 and to His344. In yet another embodiment, it will bind to the codon for Gln 173. These methods may also be used to recognize other variants of the IL-9 receptor. Another method of recognizing DNA sequence variation associated with these disorders is direct DNA sequence analysis by multiple methods well known in the art.⁴⁴ Another embodiment involves the detection of DNA sequence variation in the IL-9 receptor gene associated with these disorders.⁴⁰⁻⁴⁴ These include the polymerase chain reaction, restriction fragment length polymorphism (RFLP) analysis, and single-stranded conformational analysis. In a preferred embodiment, applicants provide specifically for a method to recognize, on a genetic level, the polymorphism in IL-9 receptor associated with the His344 and Arg344 alleles using an ASO PCR. In other embodiments, the ligation chain reaction can be used to distinguish these alleles of IL-9 receptor genes.

The present invention also includes methods for the identification of antagonists of IL-9 and its receptor. Antagonists are compounds that are themselves devoid of pharmacological activity, but cause effects by preventing the action of an agonist. To identify an antagonist of the invention, one may test for competitive binding with a known agonist or for down-regulation of IL-9-like functions as described herein and in the cited literature.^{2,22-35}

Specific assays may be used to screen for pharmaceuticals useful in treating atopic allergy based on IL-9 receptor's known role on the proliferation of T lymphocytes, IgE synthesis and release from mast cells.^{29,30,33-35} Another assay involves the ability of human IL-9 receptor to specifically induce the rapid and transient tyrosine phosphorylation of multiple proteins in Mo7e cells.³⁴ Because this response is dependent upon the expression and

activation of the IL-9 receptor, it represents a simple method or assay for the characterization of potentially valuable compounds. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the functions of the IL-9 receptor,³⁵ and this response represents a simple method or assay for the characterization of compounds within the invention. Still another method to characterize the function of the IL-9 receptor involves the use of the well known murine TS1 clone transfected with a human receptor which can be used to assess human IL-9 function with a cellular proliferation assay.²⁹ These methods can be used to identify antagonists of the IL-9 receptor.

In a further embodiment, the invention includes the down-regulation of IL-9 expression or function by administering soluble IL-9 receptor molecules that bind IL-9. Applicants and Renauld, et al.²⁹ have shown the existence of a soluble form of the IL-9 receptor. This molecule can be used to prevent the binding of IL-9 to cell-bound receptor and act as an antagonist of IL-9. Soluble receptors have been used to bind cytokines or other ligands to regulate their function.⁴⁵ A soluble receptor is a form of a membrane-bound receptor that occurs in solution, or outside of the membrane. Soluble receptors may occur because the segment of the molecule which commonly associates with the membrane is absent. This segment is commonly referred to in the art as the transmembrane domain of the gene, or membrane-binding segment of the protein. Thus, in one embodiment of the invention, a soluble receptor may represent a fragment or an analog of a membrane-bound receptor.

Applicants have identified three splice variants of the human IL-9 receptor that result in the production of proteins that could act as soluble receptors. One splice variant resulted in the deletion of exon 4 which introduced a frame-shift resulting in a stop codon as the first codon of exon 5. This variant would produce a peptide of about 45 residues that contains an epitope reactive with antibodies that block the IL-9/IL-9R interaction. The other two variants contain deletions in exon 5 that will produce premature stop codons early in the exon,

but, in these cases, without the deletion of exon 4. These variants would produce a protein of about 100 residues also containing the epitope recognized by blocking antibody.

Soluble IL-9 receptors may be used to screen for potential therapeutics, including antagonist useful in treating atopic asthma and related disorders. For example, screening for peptides and single-chain antibodies using phage display could be facilitated using a soluble receptor. Phage that bind to the soluble receptor can be isolated and the molecule identified by affinity capture of the receptor and bound phage. In addition, compound screenings for agents useful in treating atopic asthma and related disorders can incorporate a soluble receptor and ligand that bind in the absence of an antagonist. Detection of the ligand and receptor interaction occurs because of the proximity of these molecules. Antagonists are recognized by inhibiting these interactions.

In addition, the invention includes pharmaceutical compositions comprising the compounds of the invention together with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectionable solutions. Suitable pharmaceutical carriers are described in Martin, E.W., Remington's Pharmaceutical Sciences, specifically incorporated herein by reference.

The compounds used in the method of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and similar considerations.

Topical administration may be used. Any common topical formation such as a solution, suspension, gel, ointment, or salve and the like may be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pa. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. In a preferred embodiment, the compounds of this invention may be administered by inhalation. For inhalation therapy, the compound may be in a solution useful for administration by metered dose inhalers, or in a form suitable for a dry powder inhaler.

The active ingredient may be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like, or as a syrup or elixir for oral administration. For intravenous, intraperitoneal or intralesional administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intermuscular injection.

An effective amount is that amount which will down-regulate the functions controlled by IL-9 receptor. A given effective amount will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given effective amount will be best determined at the time and place through routine experimentation. It is anticipated, however, that in the treatment of asthma and related disorders in accordance with the present invention, a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 1%, will usually constitute a therapeutically effective amount. When administered systemically, an amount between 0.01 and 100 mg per kg body

weight per day, but preferably about 0.1 to 10 mg/kg, will affect a therapeutic result in most instances.

Applicants also provide for a method to screen for the compounds that down-regulate the functions controlled by the IL-9 receptor. One may determine whether the functions expressed by IL-9 receptor are down-regulated using techniques standard in the art.^{29,30,34,35} In a specific embodiment, applicants provide for a method of identifying compounds with functions comparable to IL-9. In one embodiment, the functions of IL-9 receptor may be assessed *in vitro*. As is known to those in the art, human IL-9 receptor activation specifically induces the rapid and transient tyrosine phosphorylation of multiple proteins in cells responsive to IL-9. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the actions of the IL-9 pathway. Another method to characterize the function of IL-9 and IL-9-like molecules depends on the "stable expression" of the IL-9 receptors in murine TS1 clones or TF1 clones, which do not normally express human receptor. These transfectants can be used to assess human IL-9 receptor function with a cellular proliferation assay.²⁹

The invention also includes a simple screening assay for saturable and specific ligand binding based on cell lines that express the IL-9 receptor variants.^{23,29} The IL-9 receptor is expressed in a wide variety of cell types, including K562, C8166-45, KG-1 transfected with the human IL-9 receptors, B cells, T cells, mast cells, HL60, HL60-clone 5, TS1 transfected with the human IL-9 receptors, 32D transfected with the human IL-9 receptors, neutrophils, megakaryocytes (UT-7 cells),³⁰ the human megakaryoblastic leukemia cell line Mo7e³⁴, TF1,²⁹ macrophages, eosinophiles, fetal thymocytes, the human kidney cell line 293,³⁰ and murine 32D and embryonic hippocampal progenitor cell lines.^{23,29,30}

The practice of the present invention will employ the conventional terms and techniques of molecular biology, pharmacology, immunology, and biochemistry that are within the ordinary skill of those in the art. See, for example,

Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc.

Nonetheless, we offer the following basic background information. The body's genetic material, or DNA, is arranged on 46 chromosomes, which each comprises two arms joined by a centromere. Each chromosome is divided into segments designated p or q. The symbol p is used to identify the short arm of a chromosome, as measured from the centromere to the nearest telomere. The long arm of a chromosome is designated by the symbol q. Location on a chromosome is provided by the chromosome's number (i.e., chromosome 5) as well as the coordinates of the p or q region (i.e., q31-q33). In addition, the body bears the sex chromosomes, X and Y. During meiosis, the X and Y chromosomes exchange DNA sequence information in areas known as the pseudoautosomal regions.

DNA, deoxyribonucleic acid, consists of two complementary strands of nucleotides, which include the four different base compounds, adenine (A), thymine (T), cytosine (C), and guanine (G). A of one strand bonds with T of the other strand while C of one strand bonds to G of the other to form complementary "base pairs," each pair having one base in each strand.

A sequential grouping of three nucleotides (a "codon") codes for one amino acid. Thus, for example, the three nucleotides CAG code for the amino acid Glutamine. The 20 naturally occurring amino acids, and their one-letter codes, are as follows:

Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic Acid	Asp	D
Asparagine or		
Aspartic acid	Asx	B
Cysteine	Cys	C

23

	Glutamine	Gln	Q
	Glutamine Acid	Glu	E
	Glutamine or		
	Glutamic acid	Glx	Z
5	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
10	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
15	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V

Amino acids comprise proteins. Amino acids may be hydrophilic, i.e.,
 displaying an affinity for water, or hydrophobic, i.e., having an aversion to
 20 water. Thus, the amino acids designated as G, A, V, L, I, P, F, Y, W, C and M
 are hydrophobic and the amino acids designated as S, Q, K, R, H, D, E, N and
 T are hydrophilic. In general, the hydrophilic or hydrophobic nature of amino
 acids affects the folding of a peptide chain and, consequently, the three-
 dimensional structure of a protein.

25 DNA is related to protein as follows:

genomic DNA ---> mRNA ---> protein

↑

↓

cDNA

Genomic DNA comprises all the DNA sequences found in an organism's cell. It is "transcribed" into messenger RNA ("mRNA"). Complementary DNA ("cDNA") is a complementary copy of mRNA made by reverse transcription of mRNA. Unlike genomic DNA, both mRNA and cDNA contain only the protein-encoding or polypeptide-encoding regions of the DNA, the so-called "exons." Genomic DNA may also include "introns," which do not encode proteins.

In fact, eukaryotic genes are discontinuous with proteins encoded by them, consisting of exons interrupted by introns. After transcription into RNA, the introns are removed by splicing to generate the mature messenger RNA (mRNA). The splice points between exons are typically determined by consensus sequences that act as signals for the splicing process. Splicing consists of a deletion of the intron from the primary RNA transcript and a joining or fusion of the ends of the remaining RNA on either side of the excised intron. Presence or absence of introns, the composition of introns, and number of introns per gene, may vary among strains of the same species, and among species having the same basic functional gene. Although, in most cases, introns are assumed to be nonessential and benign, their categorization is not absolute. For example, an intron of one gene can represent an exon of another. In some cases, alternate or different patterns of splicing can generate different proteins from the same single stretch of DNA. In fact, structural features of introns and the underlying splicing mechanisms form the basis for classification of different kinds of introns.

As to the exons, these can correspond to discrete domains or motifs as, for example, functional domains, folding regions, or structural elements of a protein; or to short polypeptide sequences, such as reverse turns, loops, glycosylation signals and other signal sequences, or unstructured polypeptide linker regions. The exon modules of the present combinatorial method can comprise nucleic acid sequences corresponding to naturally occurring exon

sequences or naturally occurring exon sequences which have been mutated (e.g., point mutations, truncations, fusions).

Returning now to the manipulation of DNA, DNA can be cut, spliced, and otherwise manipulated using "restriction enzymes" that cut DNA at certain known sites and DNA ligases that join DNA. Such techniques are well known to those of ordinary skill in the art, as set forth in texts such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985) or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

DNA of a specific size and sequence can then be inserted into a "replicon," which is any genetic element, such as a plasmid, cosmid, or virus, that is capable of replication under its own control. A "recombinant vector" or "expression vector" is a replicon into which a DNA segment is inserted so as to allow for expression of the DNA; i.e., production of the protein encoded by the DNA. Expression vectors may be constructed in the laboratory, obtained from other laboratories, or purchased from commercial sources.

The recombinant vector (known by various terms in the art) may be introduced into a host by a process generically known as "transformation." Transformation means the transfer of an exogenous DNA segment by any of a number of methods, including infection, direct uptake, transduction, F-mating, microinjection, or electroporation into a host cell.

Unicellular host cells, known variously as recombinant host cells, cells, and cell culture, include bacteria, yeast, insect cells, plant cells, mammalian cells and human cells. In particularly preferred embodiments, the host cells include *E.coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, Yeast, CHO, R1-1, B-W, LH, COS-J, COS-7, BSC1, BSC40, BMT10, and S69 cells. Yeast cells especially include *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, and *Torulopsis*.

As those skilled in the art recognize, the expression of the DNA segment by the host cell requires the appropriate regulatory sequences or elements. The regulatory sequences vary according to the host cell employed, but include, for

example, in prokaryotes, a promoter, ribosomal binding site, and/or a transcription termination site. In eukaryotes, such regulatory sequences include a promoter and/or a transcription termination site. As those in the art well recognize, expression of the polypeptide may be enhanced, i.e., increased over the standard levels, by careful selection and placement of these regulatory sequences.

In other embodiments, promoters that may be used include the human cytomegalovirus (CMV) promoter, tetracycline-inducible promoter, simian virus (SV40) promoter, moloney murine leukemia virus long terminal repeat (LTR) promoter, glucocorticoid inducible murine mammary tumor virus (MMTV) promoter, herpes thymidine kinase promoter, murine and human-actin promoters, HTLV1 and HIV IL-9 5' flanking region, human and mouse IL-9 receptor 5' flanking region, bacterial tac promoter and *Drosophila* heat shock protein scaffold attachment region (SAR) enhancer elements.

The DNA may be expressed as a polypeptide of any length such as peptides, oligopeptides, and proteins. Polypeptides also include translational modifications such as glycosylations, acetylations, phosphorylations, and the like.

Another molecular biologic technique of interest to the present invention is "linkage analysis." Linkage analysis is an analytic method used to identify the chromosome or chromosomal region that correlates with a trait or disorder.⁴⁷ Chromosomes are the basic units of inheritance on which genes are organized. In addition to genes, artisans have identified "DNA markers" on chromosomes. DNA markers are known sequences of DNA whose identity and sequence can be readily determined. Linkage analysis methodology has been applied to the mapping of disease genes, for example, genes relating to susceptibility to asthma, to specific chromosomes.^{47,48}

Applicants wish to incorporate by reference all the references set forth above and below.

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed. It is intended that the specification and examples be considered exemplary only with a

5 true scope of the invention being indicated by the claims.

Having provided this background information, applicants now describe preferred aspects of the invention.

EXAMPLE 1

10 Identification of IL-9 receptor transcript polymorphisms

A population of 52 individuals was ascertained randomly with respect to asthma and atopy from the Philadelphia, Pennsylvania, area. Total serum IgE were assayed by enzyme-linked immunosorbent assay (ELISA, Genzyme, Cambridge, Massachusetts).

15 To assess the structural forms of the human IL-9 receptor cDNA, PBMCs from these 52 unrelated donors were isolated and cultured in the presence of PHA and PMA (described in Example 4). Previous data from applicants' laboratory demonstrated the kinetics of expression for IL-9 receptor message in primary cultures peak at day 6 after mitogen stimulation. Applicants cultured
20 the cells, therefore, for 6 days at which time the cells were harvested and their RNA and DNA were isolated as described in Example 5.

RNAs were reverse transcribed and amplified by PCR using primers specific for full-length IL-9 receptor cDNA as described in Example 5. Amplification products from each individual were cloned into the TA PCR cloning vector and
25 ten clones containing the expected inserts (as determined by digestion and gel electrophoresis) were sequenced in their entirety and analyzed for structural or sequence variation.

Seven major variants were identified from the above screen. These cDNAs represent a codon 173 deletion, an exon 4 deletion, two separate deletions in
30 exon 5, an exon 8 deletion, and a full-length cDNA containing an ARG-to-HIS

change at codon 344 of the mature protein . Additional variants exist on each of these genetic backgrounds. The Arg allele is associated with 8 Ser/4 Asn repeats and 7 Ser/4 Asn repeats; the His allele is associated with 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn. All of these variants are depicted in Figure 1.

Variants were cloned into the eukaryotic expression vector pCEP4 (Clontech) which contains a CMV promoter that drives the expression of the cloned cDNA followed by an SV40 polyadenylation signal. The vector also contains a hygromycin B resistance gene which is used for selection of eukaryotic cells containing the vector and presumably expressing the cloned cDNA under control of the CMV promoter. Recombinant plasmids were analyzed by sequence and those plasmids containing the correct cDNA inserts were transfected into eukaryotic recipient cells such as the Syrian hamster fibroblast TK-ts13, the human glioblastoma T98G, the human myeloid leukemia line TF-1, and the murine myeloid precursor cell line 32D as described in Example 3. Function was biologically assessed as a response to the IL-9 ligand in growth and/or apoptosis (Examples 7 and 10).

Experiments in which the full-length IL-9 receptor cDNAs containing the ARG or HIS variants were performed are the TK-ts13 hamster fibroblasts or the human T98G glioblastoma cells. Cells were transfected and analyzed 48 hours later by Western blot and *in situ* staining using human specific carboxy terminal antibodies (Santa Cruz) (Example 8). *In situ* analysis demonstrated that both forms of receptor appeared to be expressed in both the hamster and human lines (Figures 11 and 12). Interestingly, while Western blots of both forms appeared to be expressed at equal levels in both the human and hamster lines, a differential migration pattern appeared between the ARG and HIS receptor forms in the TS1 cell line (Figure 12) which suggests a differential post-translational modification such as glycosylation, phosphorylation, etc. This biochemical difference may be the mechanism by which the altered function results in altered phenotype.

The frequency of the various substitutions were used as an unbiased estimate of the prevalence of each variant in the general population. Genotype was compared to phenotype assessed by questionnaire. A diagnosis of allergy and asthma was determined by a physician reviewing the questionnaires. Individuals homozygous for the Arg344 alleles were significantly less likely to demonstrate evidence for allergy and asthma when compared to heterozygotes or homozygous His344 (Figure 9).

EXAMPLE 2

Genomic analysis of the IL-9 receptor genes.

In order to perform genomic analyses of allergic and/or asthmatic individuals, the following strategy was designed to create PCR-specific primers for the authentic IL-9 receptor genes located on the X/Y pseudoautosomal regions and exclude the highly conserved IL-9 receptor pseudogenes located on chromosomes 9,10,16,and 18. First, sequence alignments were preformed between the two published pseudogenes and the genomic sequence of the IL-9 receptor genes. Primers were then initially designed in divergent regions between the authentic genes and the pseudogenes, and then analyzed by PCR using single chromosome-specific hybrids derived from Coreill DNA Repository (Camden, NJ). If the primers only produce correct sized products from X and Y hybrids, they were then optimized for robust amplification. In several cases, primers directed to the divergent regions were not XY specific; therefore, applicants introduced additional base changes in the particular primer to increase the number of mismatches higher against the pseudogenes as compared to the IL-9 receptor gene sequence. Table 1 contains the sequence of the primers and optimal annealing temperatures for XY-specific amplification. The specificity of these primers for XY amplification are demonstrated in Figure 13.

Table 1: X/Y Specific Amplimers of IL-9 Receptor

EXON	SENSE PRIMER	ANTISENSE PRIMER	TEMP	SIZE
2	5'- GCA GGT GGG GAC CCA TG -3' (SEQ ID NO 8)	5'- AGG CTT GAC ATC GGA CAA C -3' (SEQ ID NO 9)	68°	300 bp
3	5'- CTG GCC TGA AGT ACT TAC C -3' (SEQ ID NO 10)	5'- CTG CTT CAA TCC TGG GGA A -3'(SEQ ID NO 11)	62°	222 bp
4	5'- GTG AGT TCC CCA GGA TTG A -3' (SEQ ID NO 12)	5'- CAA GGC CCT GCT CCA AA -3' (SEQ ID NO 13)	64°	335 bp
5	5'- TGG GGC TTC AGC CTC ACA TG -3' (SEQ ID NO 14)	5'- TAT GTA GAG TGG GGA GTC TA -3' (SEQ ID NO 15)	62°	259 bp
6	5'- TGT ATT CTC GAG GGC TGA G -3' (SEQ ID NO 16)	5'- TGA GGT GAA CAG GGG AGA A -3' (SEQ ID NO 17)	62°	337 bp
7	5'- CCC TGG GCC CTT CAT GT -3' (SEQ ID NO 18)	5'- ACA AGG GCG GCC TTT GAT -3' (SEQ ID NO 19)	60°	262 bp
8	5'- AGG GAC GAG GTG GGC GGA C -3' (SEQ ID NO 20)	5'- CCT GCC CCC CAT GTT CTT -3' (SEQ ID NO 21)	58°	376 bp
9	5'- ATG CTA CCT GAG CCC TTC C -3' (SEQ ID NO 22)	5'- GGA CAT GAT GCA TCT GGC G -3' (SEQ ID NO 23)	62°	664 bp

These primers represent a novel method for analyzing DNA sequence variation in these genes which can be used for diagnosis of susceptibility or resistance to atopic asthma and related disorders.

Using this technology, each exon was examined by DNA sequence analyses for individuals in applicants' populations to detect sequence variation in the IL-9 receptor gene.⁴⁴ Sequence polymorphisms were distinguished from artifact by repeated analyses. An association of the receptor variants with the allergic phenotypes is set forth in Figure 9. The sequence of the receptor alleles is set forth in Figures 1-8.

EXAMPLE 3

IL-9 receptor expression and ligand binding assay

Purified recombinant IL-9 and compounds potentially resembling IL-9 in structure or function are fluorescently labeled to high specific activity by using commercially available techniques according to the supplier's recommendations (Pierce). Human Mo7e and murine 32D cells are grown and resuspended at 37°C in 0.8ml of Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine or RPMI supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine, respectively. TF1.1 (TF1 cells lacking human IL-9 receptors), T98G, TK⁻, and murine 32D cells, (Examples 7 and 10) were used as is or after transfection with the human IL-9 receptor constructs as described below. Plasmid DNA containing one of the full-length or truncated forms of IL-9 receptors were cloned into pCEP4 plasmid (Clontech) and purified by centrifugation through Qiagen columns (Qiagen). Plasmid DNA (50 micrograms) was added to the cells in 0.4 cm cuvettes just before electroporation. After a double electric pulse (750V/74 ohms/40 microfarads and 100 V/74 ohms/2100 microfarads), the cells are immediately diluted in fresh medium supplemented with IL-9.

Stable transfected cells were generated after 14 days of selection with hygromycin B (400 µg/ml to 1.6 mg/ml). Hygromycin-resistant clones were

5 analyzed for IL-9 receptor expression by Western blots and *in situ* staining as described in Example 8.

Cellular receptor binding is visualized directly in real time with fluorescence microscopy. Binding and internalization is followed over time in control cells (not transfected), and with cells transfected with each of the known IL-9 receptor
10 variants. An excess of unlabeled ligand or blocking antibody is used in parallel experiments to demonstrate specific binding.

Soluble IL-9 receptor including amino acids 44 to 270 with or without a HA ditag is also incubated with different forms of human labeled recombinant IL-9. Varying amounts of FLAG-tagged (IBI) ligand are incubated in PBS at room temperature
15 for 30 minutes with 0.5 µg of soluble receptor. EBC buffer (50 mM Tris pH 7.5; 0.1 M NaCl; 0.5% NP40) is added (300 µl) along with 1 µg of anti-HA antibody or anti-FLAG monoclonal antibody (IBI) and incubated for 1 hour on ice. Forty microliters of protein A sepharose solution were added to each sample and mixed for 1 hour at 4°C. Samples were centrifuged for 1 minute 11,000 X G and pellets
20 were washed 4 times with 500 µl of EBC. Pellets were dissolved in 26 µl of 2X SDS buffer, boiled for 4 minutes, and electrophoresed through an 18% SDS polyacrylamide gel. Western blots were probed with an anti-IL-9 receptor antibody (Santa Cruz Inc.) or anti-FLAG monoclonal antibody (IBI) against FLAG-tagged rhIL-9. Therapeutic candidates are assessed by measuring the
25 antagonism of ligand binding. Receptor expression is shown in Figures 11 and 14.

5

EXAMPLE 4

Cell Isolation and culture

Human peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by density gradient centrifugation using endotoxin tested Ficoll-Paque PLUS according to the manufacturer (Pharmacia Biotech, AB Uppsala Sweden).
10 PBMC (5×10^6), mouse spleen cells (5×10^6), or 5×10^6 Mo7e cells were cultured in 7 ml of RPMI-1640 (Bethesda Research Labs (BRL), Bethesda, MD) supplemented to a final concentration of 10% with either isogenic human serum or heat-inactivated FBS. Cells were cultured for 24 hrs at 37°C either unstimulated, or stimulated with either PMA 5 µg/ml/ PHA 5 µg/ml, or PHA 5
15 µg/ml and rhIL2 50 ng/ml (R&D Systems, Minneapolis, MN).

EXAMPLE 5

DNA & RNA isolations, rtPCR, cloning, and sequencing of PCR products

Cytoplasmic RNA and genomic DNA were extracted after 6 days of mitogen
20 stimulation from cultured PBMCs, as described by Nicolaides and Stoeckert.⁴⁶ One µg of RNA from each source was denatured for >10 minutes at 70°C and then reverse transcribed(V+) into cDNA using 2.5 units of Superscript II reverse transcriptase (GIBCO, BRL), 1U/l RNase Inhibitor, 2.5 mM oligo d(T)16 primer, 1mM each of dATP, dCTP, dGTP, dTTP, 50 mM KCl, 10 mM Tris-HCL, pH 7.0,
25 25 mM MgCl₂ at 37°C for one hour. A mock reverse transcription reaction was used as a negative control.

5 One-twentieth of the rt reaction was used in PCR (50 µl) containing 6.7 mM
MgCl₂, 16.6 mM (NH₄)₂SO₄, 67 mM Tris-HCl, pH 8.8, 10 mM 2-mercaptoethanol,
6% DMSO, 1.25 mM of each dNTP, 2.5U Amplitaq DNA polymerase, and 300 ng
of each of the oligonucleotides representing human cDNA IL-9 exon 2 (forward
10 5'-GCT GGA CCT TGG AGA GTG-3')(SEQ ID NO 25) and exon 9 (reverse 5'-GTC
TCA GAC AAG GGC TCC AG-3')(SEQ ID NO 26). The reaction mixture
subjected to the following PCR conditions: 120 seconds at 95°C, then 35 cycles
at: 30 seconds at 94°C; 90 seconds at 58°C; 90 seconds at 72°C. Finally, the
reaction mixture was cycled one time for 15 minutes at 72°C for extension.

PCR products representing hIL-9 receptor cDNA were subjected to gel
electrophoresis through 1.5% agarose gels and visualized using ethidium bromide
staining. Products of a mock reverse transcriptase reaction, in which H₂O was
substituted for RNA, were used as a negative control amplification in all
experiments.

PCR products were subcloned into the TA Cloning vector (Invitrogen, San
Diego, CA). Amplification of the human cDNA gave a 1614 bp product. Plasmids
containing hIL-9 receptor cDNA inserts were isolated by conventional techniques
(Sambrook, J., et al. (1989) Molecular Cloning: A Laboratory Manual Cold Spring
Harbor Laboratory Press, New York). After amplification the DNA sequence
including and surrounding each insert was analyzed by sequencing (Sanger et al.,
1977, Proc. Natl. Acad. Sci. USA 74:5463) using fluorescent dideoxyterminators
and on an automated sequencer (ABI 377, Perkin Elmer) for determination of
PCR-induced or cloning-induced errors. hIL-9 receptor cDNA inserts without



5 cloning and/or polymerase-induced sequence errors were subcloned into expression vectors.

EXAMPLE 6

Cloning and expression of IL-9 receptor constructs *in vitro*

10 hIL-9 receptors were subcloned into the episomal eukaryotic expression vector pCEP4 (Clontech). Inserts were cloned as BamH1-XhoI fragments into the pCEP4 polylinker in the sense orientation to the CMV promoter using standard techniques (Figure 10). Constructs were expressed in cellular hosts as described.

EXAMPLE 7

Cellular assays using (Mo7e, 32D, TF1.1, TK^{ts}13, and T98G)

15 Cell lines were used to assess the function of variant IL-9 receptors and for the screening of compounds potentially useful in the treatment of atopic asthma. Compounds were tested for their ability to antagonize the anti-apoptotic or baseline proliferative response elicited by IL-9. Once a baseline anti-apoptotic or proliferative response was established in a given cell line, a statistically significant loss of response in assays repeated three times in triplicate was considered
20 evidence for antagonism. A true antagonistic response was differentiated from cellular toxicity by direct observation, trypan blue staining (a technique well known to one of normal skill in the art), or loss of acid phosphatase activity. Specificity of antagonism is assessed for each compound by evaluating whether the activity is
25

5 demonstrated against other proliferative agents such as interleukin 3 or interleukin 4.

Recombinant IL-9 and compounds potentially resembling IL-9 in structure or function were purified and prepared for use in the appropriate media. Putative agonists and antagonists were prepared in water, saline, or DMSO and water.

10 Cells were used as is or after transfection with the IL-9 receptor constructs as described in Example 3. After 24 hrs of deprivation from growth factors, the cells were incubated without (control) or with variable amounts of purified IL-9 and compounds potentially resembling IL-9 in structure or function.

Cell proliferation was assayed using the Abacus Cell Proliferation Kit (Clontech, 15 Palo Alto, CA) which determines the amount of intracellular acid phosphatase present as an indication of cell number. The substrate p-nitrophenyl phosphate (pNPP) was converted by acid phosphatase to p-nitrophenol, which was measured as an indicator of enzyme concentration. pNPP was added to each well and incubated at 37°C for one hour. 1N sodium hydroxide was then added to 20 stop the enzymatic reaction, and the amount of p-nitrophenol was quantified using a Dynatech 2000 plate reader (Dynatech Laboratories, Chantilly, VA) at 410 nm wavelength. Standard curves that compare cell number with optical absorbance were used to determine the linear range of the assay. Assay results were only used when absorbance measurements are within the linear range of the assay.

25 Briefly, the assays were run with quadruplicate samples of cells in flat-bottom microtiter plates (150 or 200 microliter wells) with or without ligand for 72 to 96

5 hours at 37 degrees C. Acid phosphatase was used as a measure of the number of cells present. All experiments are repeated at least twice.

Apoptosis was assayed using the Annexin V kit as described by the supplier (Clontech) which determines dexamethasone-induced apoptosis by recognizing extracellular phosphatidylserine, an early marker for apoptosis. Apoptotic cell
10 number was scored by fluorescence microscopy as a percentage of Annexin V stained cells.

The Mo7e line is a human megakaryoblastic cell line, cultured in RPMI 1640 (GIBCO/BRL, Gaithersburg, MD), 20% Fetal Bovine Serum (Hyclone) and 10 ng/ml IL-3 (R&D Systems, Minneapolis, MN). The T98G line is a human
15 glioblastoma cell line grown in RPMI 1640 (GIBCO/BRL). The hamster fibroblast TK-ts13 line was also used as well as the murine 32D cell line, a murine myeloid precursor line, and both were cultured in RPMI 1640 (GIBCO/BRL) containing 10% fetal bovine serum (Hyclone) in addition 1 ng/ml m IL-3 was used with the 32
20 D cell lines. TF1.1 is a human myeloid leukemia line known to express the IL-2 receptor gamma subunit (confirmed by Western blots and rtPCR), but, in comparison to its predecessor (TF1), it no longer bears IL-9 receptor by rtPCR, immunostaining, and Western blot analyses. TF1.1 is cultured in RPMI 1640 (GIBCO/BRL) and 10% Fetal bovine serum (Hyclone). All the cell lines respond to multiple cytokines including IL-9. The cell lines were fed and reseeded at 2 X
25 10^5 cells/ml every 72 hours.

The cells were centrifuged for 10 minutes at 2000 rpm and resuspended in RPMI 1640 with 0.5% Bovine Serum Albumin (GIBCO/BRL, Gaithersburg, MD)

5 and insulin-transferrin-selenium (ITS) cofactors (GIBCO/BRL, Gaithersburg, MD). Cells were counted using a hemocytometer and diluted to a concentration of 1×10^5 cells/ml and plated in a 96-well microtiter plate. Each well contained 0.15 or 0.2 ml, giving a final concentration of 10 to 50 thousand cells per well depending on the cell. Mo7e cells were stimulated with 50 ng/ml Stem Cell Factor (SCF) (R&D Systems, Minneapolis, MN) alone, 50 ng/ml SCF plus 50 ng/ml IL-3 (R&D Systems, Minneapolis, MN), or 50 ng/ml SCF plus 50 ng/ml IL-9. A control was included which contained cells and basal media only. Serial dilutions of test compounds (i.e, recombinant IL-9 proteins, peptides, small molecules) were added to each test condition in triplicate. TF1.1 cells that were not transfected with IL-9 receptors were used as an independent control for response and nonspecific cytotoxicity. Cultures were incubated for 72-96 hours at 37°C in 5% CO₂.

EXAMPLE 8

In situ & Western analysis of exogenous IL-9 receptor in transfected cell lines

In situ staining of the IL-9 receptor was carried out as follows. Cells were grown on coverslips for 24 hours and then coverslips containing the adherent cells were washed twice in phosphate buffered saline solution containing calcium and magnesium(PBS) (Gibco/BRL). For intracellular staining of the IL-9 receptor, the cells were fixed in 4% paraformaldehyde/PBS plus 0.1% triton-X for 15 minutes at room temperature before treatment with anti-human IL-9 receptor antibody; for extracellular staining, cells were treated with antibody before fixation. The cells

5 were then washed twice in PBS and blocked with 7.5% BSA in dH₂O for 30 minutes at room temperature. PBS washed cells were then incubated with a 10 µg/ml solution of anti-human IL-9 receptor (polyclonal antibody directed against the carboxy terminus of the IL-9 receptor) in 1% BSA/PBS for 1 hour at room temperature. Cells were washed three times in PBS and then incubated in 10
10 µg/ml solution of an anti-rabbit rhodamine-conjugated antibody in 1% BSA/PBS for 30 minutes at room temperature. Cells were then washed three times in PBS and counter-stained using 1 µg/ml DAPI for 1 minute at room temperature. Cells were washed three times in dH₂O and fixed to a microscope slide and analyzed by fluorescence microscopy. The results for the transfected COS7 cells are
15 shown in Figure 14.

Western blots were performed on protein lysates obtained from direct lysis of cell extracts in 0.5% lysis buffer (Tris 50mM, NaCl 150 mM, NP40), 1 mM DTT and protease inhibitors) and boiled for 5 minutes. Samples were electrophoresed on 4-20% tris-glycine SDS gels (Novex) in tris-glycine running buffer. Proteins
20 were then transferred to nitrocellulose by electroblot using the Trans Blot II apparatus (Bio Rad). After transfer, the membrane was blocked in TBS-T ((20 mM Tris, 137 mM NaCl, pH 7.6) plus 0.05% Tween 20) plus 5% blotto for 1 hour room temperature. Blots were then probed using a polyclonal antibody directed to the carboxy terminus of the IL-9 receptor (1 µg/ml) in TBS-T for 1 hour. Blots
25 were then washed three times in TBS-T for 10 minutes and probed using a secondary anti-rabbit-horse radish peroxidase conjugated antibody (1:10,000) in TBS-T for 30 minutes. Blots were washed as above and then incubated with

5 Luminol/enhancer solution (Pierce), a chemiluminescent substrate, for 5 minutes at room temperature and then exposed to film for 1-60 seconds. See Figures 11 and 12.

10

EXAMPLE 9

Methods for the Authentic IL-9R Genomic Amplification

Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), nonprocessed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., Oncogene, 9:1327-1332, 1994; Gruss, et al., Cancer Res., 52:1026-1031, 1992), specific amplimers were designed as follows:

Sequences of the IL-9R pseudogene and authentic genes were aligned using Mac Vector software. Intronic sequences surrounding each exon were then inspected for regions of diversity between the authentic gene and pseudogenes. Primers were then designed against these regions, and used to PCR amplify

5 human/rodent hybrid DNAs containing individual human chromosomes. Products were run on 3% agarose gels and analyzed for authentic IL-9R amplification with no amplification of the 4 pseudogenes. Specific PCR amplification conditions were also optimized by varying annealing temperature and buffer conditions (DMSO content 5-10%). In cases where amplification of pseudogenes still
10 occurred, nucleotide changes were entered into primer sequences to cause greater divergence from the pseudogenes as compared to the authentic gene. Primer sequences are shown in Example 2 and their specificity is demonstrated in Figure 13.

15 EXAMPLE 10

Cell proliferation assay and cytokine stimulation

To determine growth response of TS1 cells expressing various forms of human IL-9 receptor, cells were washed with PBS and resuspended in D-MEM, 10% fetal bovine serum. 10^3 cells per well were seeded in triplicate in 96-well microplates
20 and, where appropriate, recombinant human IL-9 or murine IL-9 (R&D Systems, Minneapolis, MN) was added at a final concentration of 5 ng/ml. Cell proliferation was evaluated after 7 days using an acid phosphatase assay. Briefly, 50 μ l of a buffer containing 0.1M sodium acetate (pH 5.5), 0.1% Triton X-100 and 10mM p-nitrophenyl phosphate (Sigma 104 phosphatase substrate) was added per well.
25 The plate was incubated for 1-1/2 hours at room temperature, the reaction stopped with 10 μ l/well of 1N sodium hydroxide and the absorbance was read on a Dynatech Model MR600 at 410nm. To analyze tyrosine-phosphorylation of

5 proteins of the signal transduction cascade upon cytokine stimulation, TS1 cells expressing various forms of human IL-9 receptor were washed with PBS, resuspended in D-MEM, 0.5% bovine serum albumin, and incubated for 6 hours at 37°C. Successively, 20×10^6 cells were treated for 5 minutes with either human IL-9 or murine IL-9 (100 ng/ml) and immediately washed in cold PBS.

10 Cells were lysed in RIPA buffer as described in Example 11.

EXAMPLE 11

Immunoprecipitations, immunoblotting and antibodies

Typically, $20\text{-}50 \times 10^6$ cells were lysed in 1 ml of RIPA buffer (PBS containing

15 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 50mM sodium fluoride, 1nM sodium orthovanadate, and 1x "Complete" protease inhibitors mixture, Cat. No. 1697498 Boehringer Mannheim) and incubated for 45 minutes on ice. Lysates were centrifuged for 20 minutes in an Eppendorf microcentrifuge and the supernatant recovered and transferred to a fresh tube. For

20 immunoprecipitations, 1-5 μg of the antibody were added to the lysate and incubated overnight at 4°C. 20 ml of Protein A+G agarose-conjugated beads were added for 2 hrs followed by four washings using RIPA buffer. Beads were resuspended in Laemmli buffer and boiled for 3 minutes before electrophoresis. Proteins were transferred onto Immobilon-P membrane (Millipore) and detected

25 using a horseradish peroxidase-conjugated secondary antibody followed by a chemiluminescence detection assay (Pierce). Specific antibodies for murine and human IL-9 receptor (sc698), murine Jak1, Irs1, Irs2, Stat1, Stat2, Stat3, Stat4,

5 Stat5, and phosphotyrosine (PY) were purchased from Santa Cruz (Santa Cruz, CA). Anti-Jak3 and monoclonal anti-human IL-9 receptor MAB290 were purchased from Upstate Biotechnology and R&D Systems, respectively. Figure 15 demonstrates the activation of members of the Jak family via different variants of the human IL-9 receptor.

10

EXAMPLE 12

Identification of IL-9 receptor genomic polymorphisms

Genomic DNAs were isolated from PBMCs of volunteer donors as described (Nicolaidis and Stoeckert, Biotechniques 8:154-156, 1990). Sequence analysis of intron 5 of the human IL-9R gene was performed by PCR using primers of sequence ID NO 14 and sequence ID NO 17 which resulted in a product with the approximated molecular size of 1243 basepairs. Amplifications were carried out at 94°C for 30 seconds, 62°C for 1.5 minutes, 72°C for 1.5 minutes for 35 cycles in buffers described previously (Nicholaides et al., Genomics 30:195-206, 1995). Products were then purified and sequenced using a standard sequence protocol. Inspection of the sequences from intron 5 in multiple individuals found a nucleotide change at -213 nt upstream of exon 6 sequences which resulted in a thymidine (published sequence) to a cytosine nucleotide change. An example of this change is shown in figure 17.

20

25

While the invention has been described and illustrated herein by references to various specific materials, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and

- 5 procedures selected for that purpose.. Numerous variations of such details can be implied as will be appreciated by those skilled in the art.

5 REFERENCES

1. Gergen PJ, and Weiss KB: The increasing problem of asthma in the United States. Am Rev Respir Dis 146:823-824, 1992.
2. Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Seventh Edition, MacMillan Publishing Company, N.Y. USA, 1985.
- 10 3. Burrows B, Martinez FD, Halonen M, Barbee RA, and Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. New Eng J Med 320:271-277, 1989.
4. Clifford RD, Pugsley A, Radford M, and Holgate ST: Symptoms, atopy, and bronchial response to methacholine in parents with asthma and their
15 children. Arch Dis in Childhood 62:66-73, 1987.
5. Gergen PJ: The association of allergen skin test reactivity and respiratory disease among whites in the U.S. population. Arch Intern Med 151:487-492, 1991.
6. Burrows B, Sears MR, Flannery EM, Herbison GP, and Holdaway MD:
20 Relationship of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children. J Allergy Clin Immunol 90:376-385, 1992.
7. Johansson SGO, Bennich HH, and Berg T: The clinical significance of IgE. Prog Clin Immunol 1:1-25, 1972.
- 25 8. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, and Holdaway MD: Relation between airway responsiveness and serum IgE in

- 5 children with asthma and in apparently normal children New Engl J Med
325(15):1067-1071, 1991.
9. Halonen M, Stern D, Taussig LM, Wright A, Ray CG, and Martinez FD:
The predictive relationship between serum IgE levels at birth and subsequent
incidences of lower respiratory illnesses and eczema in infants. Am Rev Respir
10 Dis 146:666-670, 1992.
10. Marsh DG, Meyers DA, and Bias WB: The epidemiology and genetics of
atopic allergy. New Eng J Med 305:1551-1559, 1982.
11. Hopp RJ, Bewtra AK, Biven R, Nair NM, Townley RG. Bronchial reactivity
pattern in nonasthmatic parents of asthmatics. Ann Allergy 1988;61:184-186.
- 15 12. Hopp RJ, Townley RG, Biven RE, Bewtra AK, Nair NM. The presence of
airway reactivity before the development of asthma. Am Rev Respir Dis
1990;141:2-8.
13. Ackerman V, Marini M, Vittori E, et al. Detection of cytokines and their
cell sources in bronchial biopsy specimens from asthmatic patients: relationship
20 to atopic status, symptoms, and level of airway hyperresponsiveness. Chest
1994;105:687-696.
14. Hamid G, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5
in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-1546.
15. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in
25 asthma. Am Rev Respir Dis 1990;142:434-57.

- 5 16. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like
bronchoalveolar T lymphocyte population in atopic asthma. N Engl J Med
1992;326:298-304.
- 10 17. Robinson DS, Hamid Q, Ying S, et al. Prednisolone treatment in asthma
is associated with modulation of bronchoalveolar lavage cell interleukin-4,
interleukin-5, and interferon- γ cytokine gene expression. Am Rev Respir Dis
1993;148:401-406.
- 15 18. Robinson DS, Ying S, Bentley A, et al. Relationship among numbers of
bronchoalveolar lavage cells expressing messenger ribonucleic acid for
cytokines, asthma symptoms, and airway methacholine responsiveness in atopic
asthma. J Allergy Clin Immunol 1993;92:397-403.
19. O'Connor GT, Sparrow D, and Weiss ST: The role of allergy and
nonspecific BHR in the pathogenesis of COPD. Am Rev Respir Dis
140:225-252, 1989.
- 20 20. Cogswell JJ, Halliday DF, and Alexander JR: Respiratory infections in
the first year of life in children at the risk of developing atopy. Brit Med J
284:1011-1013, 1982.
21. Boushey HA, Holtzman MJ, Sheller JR, and Nadel JA: BHR. Am Rev
Respir Dis 121:389-413, 1980.
- 25 22. Renauld, J-C, Houssiau, F, Druez, C. Interleukin-9. Int Rev Exp
Pathology 1993;34A: 99-109.

- 5 23. Renauld, J-C, Kermouni, A, Vink, A, Louahed, J, Van Snick, J.
Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell
oncogenesis. J Leukoc Biol 1995;57:353-360.
- 10 24. Hultner, L, Moeller, J, Schmitt, E, Jager, G, Reisbach, G, Ring, J, Dormer,
P. Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a
mast cell growth-enhancing activity different from both IL-3 and IL-4. J Immunol
1989;142:3440-3446.
- 15 25. Dugas, B, Renauld, J-C, Pene, J, Bonnefoy, J, Peti-Frere, C, Braquet, P,
Bousquet, J, Van Snick, J, Mencia-Huerta, JM. Interleukin-9 potentiates the
interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal
human B lymphocytes. Eur J Immunol 1993;23:1687-1692.
- 20 26. Petit-Frere, C, Dugas, B, Braquet, P, Mencia-Huerta, JM. Interleukin-9
potentiates the interleukin-4-induced IgE and IgG1 release from murine B
lymphocytes. Immunology 1993;79:146-151.
- 25 27. Behnke, JM, Wahid, FN, Grencis, RK, Else, KJ, Ben-Smith, AW, Goyal,
PK. Immunological relationships during primary infection with *Heligmosomoides*
polygyrus (*Nematospiroides dubius*): downregulation of specific cytokine
secretion (IL-9 and IL-10) correlates with poor mastocytosis and chronic survival
of adult worms. Parasite Immunol 1993;15:415-421.
- 25 28. Gessner, A, Blum, H, Rollinghoff, M. Differential regulation of IL-9
expression after infection with *Leishmania major* in susceptible and resistant
mice. Immunobiology 1993;189:419-435.

- 5 29. Renauld J-C, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci 89:5690-5694(1992).
30. Chang M-S, Engel G, Benedict C et al. Isolation and characterization of the Human interleukin-9 receptor gene. Blood 83:3199-3205(1994).
- 10 31. Renauld J-C, Goethals A, Houssiau F, et al. Human P40/IL-9. Expression in activated CD4+ T cells, Genomic Organization, and Comparison with the Mouse Gene. J Immunol 144:4235-4241(1990).
32. Kelleher K, Bean K, Clark SC, et al. Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in
- 15 human T-cell leukemia virus (HTLV-I-transformed human T cells. Blood 77:1436-1441(1991).
33. Houssiau FA, Schandene L, Stevens M, et al. A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. J of Immunol. 154:2624-2630(1995).
- 20 34. Miyazawa K, Hendrie PC, Kim Y-J, et al. Recombinant human interleukin-9 induces protein tyrosine phosphorylation and synergizes with steel factor to stimulate proliferation of the human factor-dependent cell line, Mo7e. Blood 80:1685-1692(1992).
35. Yin T, Tsang M L-S, Yang Y-C. JAK1 kinase forms complexes with
- 25 interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes. J Biol Chem 269:26614-26617(1994).

- 5 36. Zav'yalov VP, Navolotskaya EV, Isaev IS, et al. Nonapeptide corresponding to the sequence 27-35 of the mature human IL-2 efficiently competes with rIL-2 for binding to thymocyte receptors. Immunol Lett 31:285-288(1992).
- 10 37. Chu JW, and Sharom FJ. Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. Cell Immunol 145:223-239(1992).
38. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324-328(1992).
- 15 39. Morely J. Cyclosporin A in asthma therapy: a pharmacological rationale. J Autoimmun 5 Suppl A:265-269(1992).
40. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, and Stone EM: The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325-332, 1993.
- 20 41. Orita M, Suzuki Y, Sekiya T, and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-9, 1989.
42. Sarkar G, Yoon H-S, and Sommer SS: Dideoxy fingerprint (ddF): A rapid and efficient screen for the presence of mutations. Genomics 13:441-443, 1992.
- 25 43. Cotton RG: Detection of single base changes in nucleic acids. Biochemical Journal 263(1):1-10, 1989.
44. Schwengel D, Nouri N, Meyers D, and Levitt RC: Linkage mapping of the human thromboxane A2 receptor (TBXA2R) to chromosome 19p13.3 using

- 5 transcribed 3' untranslated DNA sequence polymorphisms. Genomics
18:212-215, 1993.
45. Cytokine Handbook, Angus Thomson (1994).
46. Nicolaides, N.C. and Stoecker, C.J. A simple, efficient method for the
separate isolation of RNA and DNA from the same cells. Biotechniques
10 1996;8:154-156.
47. Ott J. Analysis of Human Genetic Linkage. Baltimore, Maryland: The
Johns Hopkins University Press, 1991.
48. Meyers DA, Postma DS, Panhuysen CIM, et al. Evidence for a locus
regulating total serum IgE levels mapping to chromosome 5. Genomics
15 1994;23:464 470.41.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: MAGAININ PHARMACEUTICALS, INC.
- (ii) TITLE OF INVENTION: IL-9 Receptor Variants, Useful in Treating and Diagnosing Atopic Allergies Including Asthma and Related Disorders
- (iii) NUMBER OF SEQUENCES: 36
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: F. B. Rice & Co.
 - (B) STREET: 605 Darling St.
 - (C) CITY: Balmain
 - (D) STATE: New South Wales
 - (E) COUNTRY: Australia
 - (F) ZIP: 2041
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: AU 56891/98
 - (B) FILING DATE: 02-DEC-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/032,224
 - (B) FILING DATE: 02-DEC-1996
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/980,872
 - (B) FILING DATE: 01-DEC-1997
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US97/21992
 - (B) FILING DATE: 02-DEC-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME:
 - (B) REGISTRATION NUMBER:
 - (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 61 2 6283 2211
 - (B) TELEFAX: 61 2 6285 3593

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1705 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear



(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT	60
GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT	120
CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC	180
CTCTTCACCA GCAACCAGGC TCCTGGCGGC ACACATAAGT GCATCTTGCG GGGCAGTGAG	240
TGCACCGTCG TGCTGCCACC TGAGGCAGTG CTCGTGCCAT CTGACAATTT CACCATCACT	300
TTCCACCACT GCATGTCTGG GAGGGAGCAG GTCAGCCTGG TGGACCCGGA GTACCTGCCC	360
CGGAGACACG TTAAGCTGGA CCCGCCCTCT GACTTGCAGA GCAACATCAG TTCTGGCCAC	420
TGCATCCTGA CCTGGAGCAT CAGTCCTGCC TTGGAGCCAA TGACCACACT TCTCAGCTAT	480
GAGCTGGCCT TCAAGAAGCA GGAAGAGGCC TGGGAGCAGG CCCAGCACAG GGATCACATT	540
GTCGGGGTGA CCTGGCTTAT ACTTGAAGCC TTTGAGCTGG ACCCTGGCTT TATCCATGAG	600
GCCAGGCTGC GTGTCCAGAT GGCCACACTG GAGGATGATG TGGTAGAGGA GGAGCGTTAT	660
ACAGGCCAGT GGAGTGAGTG GAGCCAGCCT GTGTGCTTCC AGGCTCCCCA GAGACAAGGC	720
CCTCTGATCC CACCCTGGGG GTGGCCAGGC AACACCCTTG TTGCTGTGTC CATCTTTCTC	780
CTGCTGACTG GCCCGACCTA CCTCCTGTTC AAGCTGTCGC CCAGGGTGAA GAGAATCTTC	840
TACCAGAACG TGCCCTCTCC AGCGATGTTC TTCCAGCCCC TCTACAGTGT ACACAATGGG	900
AACTTCCAGA CTTGGATGGG GGCCACAGG GCCGGTGTGC TGTTGAGCCA GGAAGTGTCT	960
GGCACCCAC AGGGAGCCTT GGAGCCCTGC GTCCAGGAGG CCACTGCACT GCTCACTTGT	1020
GGCCAGCGC GTCCTTGGA ATCTGTGGCC CTGGAGGAGG AACAGGAGG CCCTGGGACC	1080
AGGCTCCCGG GGAACCTGAG CTCAGAGGAT GTGCTGCCAG CAGGGTGTAC GGAGTGGAGG	1140
GTACAGACGC TTGCCTATCT GCCACAGGAG GACTGGGCCC CCACGTCCCT GACTAGGCCG	1200
GCTCCCCCAG ACTCAGAGGG CAGCAGGAGC AGCAGCAGCA GCAGCAGCAG CAGCAACAAC	1260
AACAATACT GTGCCTTGGG CTGCTATGGG GGATGGCACC TCTCAGCCCT CCCAGGAAAC	1320
ACACAGAGCT CTGGGCCCCAT CCCAGCCCTG GCCTGTGGCC TTTCTTGTGA CCATCAGGGC	1380
CTGGAGACCC AGCAAGGAGT TGCCCTGGGTG CTGGCTGGTC ACTGCCAGAG GCCTGGGCTG	1440
CATGAGGACC TCCAGGGCAT GTTGCTCCCT TCTGTCCTCA GCAAGGCTCG GTCCTGGACA	1500
TTCTAGGTCC CTGACTCGCC AGATGCATCA TGTCCATTTT GGGAAAATGG ACTGAAGTTT	1560
CTGGAGCCCT TGTCTGAGAC TGAACCTCCT GAGAAGGGGC CCCTAGCAGC GGTGAGAGGT	1620
CCTGTCTGGA TGGAGGCTGG AGGCTCCCCC CTCAACCCCT CTGCTCAGTG CCTGTGGGGA	1680
GCAGCCTCTA CCCTCAGCAT CCTGG	1705



(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1705 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
 - (B) LOCATION: 1..1705
 - (D) OTHER INFORMATION: /note= "Nucleotides 1 to 1705 correspond to nucleotides 243 to 1947 of Fig. 3.
- Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 1 of SEQ ID NO: 2."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT	60
GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT	120
CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC	180
CTCTTCACCA GCAACCAGGC TCCTGGCGGC ACACATAAGT GCATCTTGCG GGGCAGTGAG	240
TGCACCGTCG TGCTGCCACC TGAGGCAGTG CTCGTGCCAT CTGACAATTT CACCATCACT	300
TTCCACCACT GCATGTCTGG GAGGGAGCAG GTCAGCCTGG TGGACCCGGA GTACCTGCCC	360
CGGAGACACG TTAAGCTGGA CCCGCCCTCT GACTTGCGA GCAACATCAG TTCTGGCCAC	420
TGCATCCTGA CCTGGAGCAT CAGTCCTGCC TTGGAGCCAA TGACCACACT TCTCAGCTAT	480
GAGCTGGCCT TCAAGAAGCA GGAAGAGGCC TGGGAGCAGG CCCAGCACAG GGATCACATT	540
GTCGGGGTGA CCTGGCTTAT ACTTGAAGCC TTTGAGCTGG ACCCTGGCTT TATCCATGAG	600
GCCAGGCTGC GTGTCCAGAT GGCCACACTG GAGGATGATG TGGTAGAGGA GGAGCGTTAT	660
ACAGGCCAGT GGAGTGAGTG GAGCCAGCCT GTGTGCTTCC AGGCTCCCCA GAGACAAGGC	720
CCTCTGATCC CACCCTGGGG GTGGCCAGGC AACACCCTTG TTGCTGTGTC CATCTTTCTC	780
CTGCTGACTG GCCCAGACCTA CCTCCTGTTC AAGCTGTCGC CCAGGGTGAA GAGAATCTTC	840
TACCAGAACG TGCCCTCTCC AGCGATGTTT TTCCAGCCCC TCTACAGTGT ACACAATGGG	900
AACTTCCAGA CTTGGATGGG GGCCACAGG GCCGGTGTGC TGTGAGCCA GGACTGTGCT	960
GGCACCCAC AGGGAGCCTT GGAGCCCTGC GTCCAGGAGG CCACTGCACT GCTCACTTGT	1020
GGCCCAGCGC ATCCTTGGA ATCTGTGGCC CTGGAGGAGG AACAGGAGGG CCCTGGGACC	1080
AGGCTCCCGG GGAACCTGAG CTCAGAGGAT GTGCTGCCAG CAGGGTGTAC GGAGTGAGG	1140
GTACAGACGC TTGCCTATCT GCCACAGGAG GACTGGGCCC CCACGTCCCT GACTAGGCCG	1200
GCTCCCCAG ACTCAGAGG CAGCAGGAGC AGCAGCAGCA GCAGCAGCAG CAGCAACAAC	1260



AACAAC TACT GTGCCTTGGG CTGCTATGGG GGATGGCACC TCTCAGCCCT CCCAGGAAAC	1320
ACACAGAGCT CTGGGCCCCAT CCCAGCCCTG GCCTGTGGCC TTTCTTGTGA CCATCAGGGC	1380
CTGGAGACCC AGCAAGGAGT TGCCTGGGTG CTGGCTGGTC ACTGCCAGAG GCCTGGGCTG	1440
CATGAGGACC TCCAGGGCAT GTTGCTCCCT TCTGTCCTCA GCAAGGCTCG GTCCTGGACA	1500
TTCTAGGTCC CTGACTCGCC AGATGCATCA TGTCCATTTT GGGAAAATGG ACTGAAGTTT	1560
CTGGAGCCCT TGTCTGAGAC TGAACCTCCT GAGAAGGGGC CCCTAGCAGC GGTCAGAGGT	1620
CCTGTCTGGA TGGAGGCTGG AGGCTCCCCC CTCAACCCCT CTGCTCAGTG CCTGTGGGGA	1680
GCAGCCTCTA CCCTCAGCAT CCTGG	1705

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1702 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc feature

(B) LOCATION: 1..1702

(D) OTHER INFORMATION: /note= "Nucleotides 1 to 1702 correspond to nucleotides 243 to 1944 of Fig. 5.

Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 1 of SEQ ID NO: 3."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT	60
GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT	120
CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC	180
CTCTTCACCA GCAACCAGGC TCCTGGCGGC ACACATAAGT GCATCTTGCG GGGCAGTGAG	240
TGCACCGTCG TGCTGCCACC TGAGGCAGTG CTCGTGCCAT CTGACAATTT CACCATCACT	300
TTCCACCACT GCATGTCTGG GAGGGAGCAG GTCAGCCTGG TGGACCCGGA GTACCTGCCC	360
CGGAGACACG TTAAGCTGGA CCCGCCCTCT GACTTG CAGA GCAACATCAG TTCTGGCCAC	420
TGCATCCTGA CCTGGAGCAT CAGTCCTGCC TTGGAGCCAA TGACCACACT TCTCAGCTAT	480
GAGCTGGCCT TCAAGAAGCA GGAAGAGGCC TGGGAGGCC AGCACAGGGA TCACATTGTC	540
GGGGTGACCT GGCTTATACT TGAAGCCTTT GAGCTGGACC CTGGCTTTAT CCATGAGGCC	600
AGGCTGCGTG TCCAGATGGC CACACTGGAG GATGATGTGG TAGAGGAGGA GCGTTATACA	660
GGCCAGTGGA GTGAGTGGAG CCAGCCTGTG TGCTTCCAGG CTCCCCAGAG ACAAGGCCCT	720
CTGATCCAC CCTGGGGGTG GCCAGGCAAC ACCCTTGTTG CTGTGTCCAT CTTTCTCCTG	780



CTGACTGGCC CGACCTACCT CCTGTTCAAG CTGTCGCCCCA GGGTGAAGAG AATCTTCTAC	840
CAGAACGTGC CCTCTCCAGC GATGTTCTTC CAGCCCCCTCT ACAGTGTACA CAATGGGGAAC	900
TTCCAGACTT GGATGGGGGC CCACAGGGCC GGTGTGCTGT TGAGCCAGGA CTGTGCTGGC	960
ACCCACAGG GAGCCTTGA GCCCTGCGTC CAGGAGGCCA CTGCACTGCT CACTTGTGGC	1020
CCAGCGCGTC CTTGGAAATC TGTGGCCCTG GAGGAGGAAC AGGAGGGCCC TGGGACCAGG	1080
CTCCCGGGGA ACCTGAGCTC AGAGGATGTG CTGCCAGCAG GGTGTACGGA GTGGAGGGTA	1140
CAGACGCTTG CCTATCTGCC ACAGGAGGAC TGGGCCCCCA CGTCCCTGAC TAGGCCGGCT	1200
CCCCCAGACT CAGAGGGCAG CAGGAGCAGC AGCAGCAGCA GCAGCAGCAG CAACAACAAC	1260
AACTACTGTG CCTTGGGCTG CTATGGGGGA TGGCACCTCT CAGCCCTCCC AGGAAACACA	1320
CAGAGCTCTG GGCCCATCCC AGCCCTGGCC TGTGGCCTTT CTTGTGACCA TCAGGGCCTG	1380
GAGACCCAGC AAGGAGTTGC CTGGGTGCTG GCTGGTCACT GCCAGAGGCC TGGGCTGCAT	1440
GAGGACCTCC AGGGCATGTT GCTCCCTTCT GTCCTCAGCA AGGCTCGGTC CTGGACATTC	1500
TAGGTCCCTG ACTCGCCAGA TGCATCATGT CCATTTTGGG AAAATGGACT GAAGTTTCTG	1560
GAGCCCTTGT CTGAGACTGA ACCTCCTGAG AAGGGGCCCC TAGCAGCGGT CAGAGGTCCT	1620
GTCTGGATGG AGGCTGGAGG CTCCCCCCTC AACCCTCTG CTCAGTGCCT GTGGGGAGCA	1680
GCCTCTACCC TCAGCATCCT GG	1702

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 861 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..861

(D) OTHER INFORMATION: /note= "Nucleotides 1 to 861 correspond to nucleotides 243 to 1103 of Fig. 4.
Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 1 of SEQ ID NO: 4."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT	60
GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT	120
CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC	180
CTCTTCACCA GCAACCAGGC TCCTGGCGGC ACACATAAGT GCATCTTGCG GGGCAGTGAG	240
TGCACCGTCG TGCTGCCACC TGAGGCAGTG CTCGTGCCAT CTGACAATTT CACCATCACT	300



TTCCACCACT GCATGTCTGG GAGGGAGCAG GTCAGCCTGG TGGACCCGGA GTACCTGCCC 360
 CGGAGACACG TTAAGCTGGA CCCGCCCTCT GACTTGCAGA GCAACATCAG TTCTGGCCAC 420
 TGCATCCTGA CCTGGAGCAT CAGTCCTGCC TTGGAGCCAA TGACCACACT TCTCAGCTAT 480
 GAGCTGGCCT TCAAGAAGCA GGAAGAGGCC TGGGAGCAGG CCCAGCACAG GGATCACATT 540
 GTCGGGGTGA CCTGGCTTAT ACTTGAAGCC TTTGAGCTGG ACCCTGGCTT TATCCATGAG 600
 GCCAGGCTGC GTGTCCAGAT GGCCACACTG GAGGATGATG TGGTAGAGGA GGAGCGTTAT 660
 ACAGGCCAGT GGAGTGAGTG GAGCCAGCCT GTGTGCTTCC AGGCTCCCCA GAGACAAGGC 720
 CCTCTGATCC CACCCTGGGG GTGGCCAGGC AACACCCTTG TTGCTGTGTC CATCTTTCTC 780
 CTGCTGACTG GCCCCACCTA CCTCCTGTTC AAGCTGTCGC CCAGACTTGG ATGGGGGGCC 840
 ACAGGGCCGG TGTGCTGTTG A 861

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 195 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..195

(D) OTHER INFORMATION: /note= "Nucleotide nos. 1 to 195 correspond to nucleotides 243 to 437 of Fig. 8.
 Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 1 of SEQ ID NO: 5."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT 60
 GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT 120
 CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC 180
 CTCTTCACCA GTTAA 195

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:


- (A) LENGTH: 513 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..513

(D) OTHER INFORMATION: /note= "Nucleotide nos. 1 to 513 correspond to nucleot



Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 36 of SEQ ID NO: 6."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTC CTGGCCTGCA	60
TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTCAC AGGGGAAGGA CAAGGGCCAA	120
GGTCTAGAAC CTTACCTGC CTCACCAACA ACATTCTCAG GATCGATTGC CACTGGTCTG	180
CCCCAGAGCT GGGACAGGGC TCCAGCCCCT GGCTCCTCTT CACCAGCAAC CAGGCTCCTG	240
GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTG CCACCTGAGG	300
CAGTGCTCGT GCCATCTGAC AATTTACCA TCACTTTCCA CCACTGCATG TCTGGGAGGG	360
AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACACGCTGGA CCCGCCCTCT	420
GACTTGACAGA GCAACATCAG TTCTGGCCAC TGCATCCTGA CCTGGAGCAT CAGTCCTGCC	480
TTGGAGCCAA TGACCACACT TCTCAGCTAT GAG	513

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 513 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..513

(D) OTHER INFORMATION: /note= "Nucleotides 1 to 513 correspond to nucleotides 208 to 720 of Fig. 7.

Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 36 of SEQ ID NO: 7."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTC CTGGCCTGCA	60
TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTCAC AGGGGAAGGA CAAGGGCCAA	120
GGTCTAGAAC CTTACCTGC CTCACCAACA ACATTCTCAG GATCGATTGC CACTGGTCTG	180
CCCCAGAGCT GGGACAGGGC TCCAGCCCCT GGCTCCTCTT CACCAGCAAC CAGGCTCCTG	240
GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTG CCACCTGAGG	300
CAGTGCTCGT GCCATCTGAC AATTTACCA TCACTTTCCA CCACTGCATG TCTGGGAGGG	360
AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACACGAGCAA CATCAGTTCT	420
GGCCACTGCA TCCTGACCTG GAGCATCAGT CCTGCCTTGG AGCCAATGAC CAACTTCTC	480
AGCTATGAGC TGGCCTTCAA GAAGCAGGAA GAG	513



(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCAGGTGGGG ACCCATG

17

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGGCTTGACA TCGGACAAC

19

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTGGCCTGAA GTACTTACC

19

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGCTTCAAT CCTGGGGAA

19



(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTGAGTTCCC CAGGATTGA

19

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAAGGCCCTG CTCCAAA

17

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGGGCTTCA GCCTCACATG

20

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear


(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TATGTAGAGT GGGGAGTCTA

20

(2) INFORMATION FOR SEQ ID NO:16:



- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGTATTCTCG AGGGCTGAG

19

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGAGGTGAAC AGGGGAGAA

19

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCCTGGGCCC TTCATGT

17

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear


(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACAAGGGCGG CCTTTGAT

18

(2) INFORMATION FOR SEQ ID NO:20:



- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGGGACGAGG TGGGCGGAC

19

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCTGCCCCC ATGTTCTT

18

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATGCTACCTG AGCCCTTCC

19

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid


(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGACATGATG CATCTGGCG

19

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:



- (A) LENGTH: 1702 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: mutation
- (B) LOCATION: 1264..1266
- (D) OTHER INFORMATION: /note= "This codon in the wild type is deleted."

(A) NAME/KEY: misc_feature


(B) LOCATION: 1..1702

(D) OTHER INFORMATION: /note= "Nucleotides 1 to 1702 correspond to nucleotides 243 to 1944 of Fig. 2.

Nucleotide 1 of SEQ ID NO: 1 corresponds to nucleotide 1 of SEQ ID NO: 24."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATGGGCACCT GGCTCCTGGC CTGCATCTGC ATCTGCACCT GTGTCTGCTT GGGAGTCTCT	60
GTCACAGGGG AAGGACAAGG GCCAAGGTCT AGAACCTTCA CCTGCCTCAC CAACAACATT	120
CTCAGGATCG ATTGCCACTG GTCTGCCCCA GAGCTGGGAC AGGGCTCCAG CCCCTGGCTC	180
CTCTTCACCA GCAACCAGGC TCCTGGCGGC ACACATAAGT GCATCTTGCG GGGCAGTGAG	240
TGCACCGTCG TGCTGCCACC TGAGGCAGTG CTCGTGCCAT CTGACAATTT CACCATCACT	300
TTCCACCACT GCATGTCTGG GAGGGAGCAG GTCAGCCTGG TGGACCCGGA GTACCTGCCC	360
CGGAGACACG TTAAGCTGGA CCCGCCCTCT GACTTGACAG GCAACATCAG TTCTGGCCAC	420
TGCATCCTGA CCTGGAGCAT CAGTCCTGCC TTGGAGCCAA TGACCACACT TCTCAGCTAT	480
GAGCTGGCCT TCAAGAAGCA GGAAGAGGCC TGGGAGCAGG CCCAGCACAG GGATCACATT	540
GTCGGGGTGA CCTGGCTTAT ACTTGAAGCC TTTGAGCTGG ACCCTGGCTT TATCCATGAG	600
GCCAGGCTGC GTGTCCAGAT GGCCACACTG GAGGATGATG TGGTAGAGGA GGAGCGTTAT	660
ACAGGCCAGT GGAGTGAGTG GAGCCAGCCT GTGTGCTTCC AGGCTCCCCA GAGACAAGGC	720
CCTCTGATCC CACCCTGGGG GTGGCCAGGC AACACCCTTG TTGCTGTGTC CATCTTTCTC	780
CTGCTGACTG GCCCGACCTA CCTCCTGTTC AAGCTGTCGC CCAGGGTGAA GAGAATCTTC	840
TACCAGAACG TGCCCTCTCC AGCGATGTTC TTCCAGCCCC TCTACAGTGT ACACAATGGG	900
AACTTCCAGA CTTGGATGGG GGCCACAGG GCCGGTGTGC TGTTGAGCCA GGAAGTGCTG	960
GGCACCCAC AGGGAGCCTT GGAGCCCTGC GTCCAGGAGG CCACTGCACT GCTCACTTGT	1020
GGCCCAGCGC GTCCTTGGA ATCTGTGGCC CTGGAGGAGG AACAGGAGGG CCCTGGGACC	1080
AGGCTCCCGG GGAACCTGAG CTCAGAGGAT GTGCTGCCAG CAGGGTGTAC GGAGTGAGG	1140
GTACAGACGC TTGCCTATCT GCCACAGGAG GACTGGGCCC CCACGTCCCT GACTAGGCCG	1200



GCTCCCCCAG ACTCAGAGGG CAGCAGGAGC AGCAGCAGCA GCAGCAGCAG CAGCAACAAC	1260
AACTACTGTG CCTTGGGCTG CTATGGGGGA TGGCACCTCT CAGCCCTCCC AGGAAACACA	1320
CAGAGCTCTG GGCCCATCCC AGCCCTGGCC TGTGGCCTTT CTTGTGACCA TCAGGGCCTG	1380
GAGACCCAGC AAGGAGTTGC CTGGGTGCTG GCTGGTCACT GCCAGAGGCC TGGGCTGCAT	1440
GAGGACCTCC AGGGCATGTT GCTCCCTTCT GTCCTCAGCA AGGCTCGGTC CTGGACATTC	1500
TAGGTCCCTG ACTCGCCAGA TGCATCATGT CCATTTTGGG AAAATGGACT GAAGTTTCTG	1560
GAGCCCTTGT CTGAGACTGA ACCTCCTGAG AAGGGGCCCC TAGCAGCGGT CAGAGGTCCT	1620
GTCTGGATGG AGGCTGGAGG CTCCCCCTC AACCCCTCTG CTCAGTGCCT GTGGGGAGCA	1680
GCCTCTACCC TCAGCATCCT GG	1702

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCTGGACCTT GGAGAGTG

18

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTCTCAGACA AGGGCTCCAG

20


(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:


- (A) LENGTH: 501 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:



Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15
 Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30
 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45
 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60
 Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80
 Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95
 Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110
 Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
 115 120 125
 Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
 130 135 140
 Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
 145 150 155 160
 Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His
 165 170 175
 Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu
 180 185 190
 Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala
 195 200 205
 Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp
 210 215 220
 Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly
 225 230 235 240
 Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255
 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270
 Ser Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala
 275 280 285
 Met Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr
 290 295 300
 Trp Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala
 305 310 315 320
 Gly Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala



- (ii) MOLECULE TYPE: peptide

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
50 55 60



65	70	75	80
Cys Thr Val Val	Leu Pro Pro Glu Ala	Val Leu Val Pro Ser Asp Asn	
	85	90	95
Phe Thr Ile Thr	Phe His His Cys Met	Ser Gly Arg Glu Gln Val Ser	
	100	105	110
Leu Val Asp Pro	Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro		
	115	120	125
Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr			
	130	135	140
Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr			
	145	150	155
Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His			
	165	170	175
Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu			
	180	185	190
Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala			
	195	200	205
Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp			
	210	215	220
Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly			
	225	230	235
Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val			
	245	250	255
Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu			
	260	265	270
Ser Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala			
	275	280	285
Met Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr			
	290	295	300
Trp Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala			
	305	310	315
Gly Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala			
	325	330	335
Leu Leu Thr Cys Gly Pro Ala His Pro Trp Lys Ser Val Ala Leu Glu			
	340	345	350
Glu Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser			
	355	360	365
Glu Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu			
	370	375	380
Ala Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro			
	385	390	395
			400



Ala Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser Ser
 405 410 415

Ser Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp
 420 425 430

His Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro
 435 440 445

Ala Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln
 450 455 460

Gln Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu
 465 470 475 480

His Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala
 485 490 495

Arg Ser Trp Thr Phe
 500

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95


Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
 115 120 125

Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
 130 135 140



Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
 145 150 155 160
 Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Ala Gln His Arg
 165 170 175
 Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu Leu
 180 185 190
 Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala Thr
 195 200 205
 Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp Ser
 210 215 220
 Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly Pro
 225 230 235 240
 Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val Ser
 245 250 255
 Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu Ser
 260 265 270
 Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala Met
 275 280 285
 Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr Trp
 290 295 300
 Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala Gly
 305 310 315 320
 Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala Leu
 325 330 335
 Leu Thr Cys Gly Pro Ala Arg Pro Trp Lys Ser Val Ala Leu Glu Glu
 340 345 350
 Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser Glu
 355 360 365
 Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu Ala
 370 375 380
 Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro Ala
 385 390 395 400
 Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp His
 420 425 430
 Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro Ala
 435 440 445
 Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln Gln
 450 455 460



Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu His
 465 470 475 480

Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala Arg
 485 490 495

Ser Trp Thr Phe
 500

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 286 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
 115 120 125


Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
 130 135 140

Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
 145 150 155 160

Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His
 165 170 175

Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu
 180 185 190

Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala
 195 200 205



Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp
 210 215 220
 Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly
 225 230 235 240
 Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255
 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270
 Ser Pro Arg Leu Gly Trp Gly Pro Thr Gly Pro Val Cys Cys
 275 280 285

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15
 Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30
 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45
 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

(2) INFORMATION FOR SEQ ID NO:32:


(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 128 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15
 Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30
 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45



Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Ala Gly Pro Ala Leu
 115 120 125

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95


Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
 100 105 110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Glu Gln His Gln Phe
 115 120 125

Trp Pro Leu His Pro Asp Leu Glu His Gln Ser Cys Leu Gly Ala Asn
 130 135 140

Asp His Thr Ser Gln Leu
 145 150

(2) INFORMATION FOR SEQ ID NO:34:



(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: MUTATION
- (B) LOCATION: 422
- (D) OTHER INFORMATION: /note= "Asn at this position in the wild type is deleted."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
1           5           10           15

Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
20           25           30

Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
35           40           45

Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
50           55           60

Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
65           70           75           80

Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
85           90           95

Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser
100          105          110

Leu Val Asp Pro Glu Tyr Leu Pro Arg Arg His Val Lys Leu Asp Pro
115          120          125

Pro Ser Asp Leu Gln Ser Asn Ile Ser Ser Gly His Cys Ile Leu Thr
130          135          140

Trp Ser Ile Ser Pro Ala Leu Glu Pro Met Thr Thr Leu Leu Ser Tyr
145          150          155          160

Glu Leu Ala Phe Lys Lys Gln Glu Glu Ala Trp Glu Gln Ala Gln His
165          170          175


Arg Asp His Ile Val Gly Val Thr Trp Leu Ile Leu Glu Ala Phe Glu
180          185          190

Leu Asp Pro Gly Phe Ile His Glu Ala Arg Leu Arg Val Gln Met Ala
195          200          205

Thr Leu Glu Asp Asp Val Val Glu Glu Glu Arg Tyr Thr Gly Gln Trp
210          215          220

Ser Glu Trp Ser Gln Pro Val Cys Phe Gln Ala Pro Gln Arg Gln Gly
225          230          235          240

```




Pro Leu Ile Pro Pro Trp Gly Trp Pro Gly Asn Thr Leu Val Ala Val
 245 250 255
 Ser Ile Phe Leu Leu Leu Thr Gly Pro Thr Tyr Leu Leu Phe Lys Leu
 260 265 270
 Ser Pro Arg Val Lys Arg Ile Phe Tyr Gln Asn Val Pro Ser Pro Ala
 275 280 285
 Met Phe Phe Gln Pro Leu Tyr Ser Val His Asn Gly Asn Phe Gln Thr
 290 295 300
 Trp Met Gly Ala His Arg Ala Gly Val Leu Leu Ser Gln Asp Cys Ala
 305 310 315 320
 Gly Thr Pro Gln Gly Ala Leu Glu Pro Cys Val Gln Glu Ala Thr Ala
 325 330 335
 Leu Leu Thr Cys Gly Pro Ala Arg Pro Trp Lys Ser Val Ala Leu Glu
 340 345 350
 Glu Glu Gln Glu Gly Pro Gly Thr Arg Leu Pro Gly Asn Leu Ser Ser
 355 360 365
 Glu Asp Val Leu Pro Ala Gly Cys Thr Glu Trp Arg Val Gln Thr Leu
 370 375 380
 Ala Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro
 385 390 395 400
 Ala Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Ser Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp His
 420 425 430
 Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro Ala
 435 440 445
 Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln Gln
 450 455 460
 Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu His
 465 470 475 480
 Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala Arg
 485 490 495
 Ser Trp Thr Phe
 500

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 70 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA



(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..70

(D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base no. 81 of intron 5."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AAGTGTGATG AGTGTGAAAG TGTTCTGTGA GACATGTTTG CCTGTGTGTG CATATGTGTA 60

TTTGTGGGCA 70

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..70

(D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base no. 81 of intron 5."

(ix) FEATURE:

(A) NAME/KEY: mutation

(B) LOCATION: 133

(D) OTHER INFORMATION: /note= "T to C substitution in intron 5."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

AAGTGTGATG AGTGTGAAAG TGTTCTGTGA GACATGTTTG CCTGTGTGTG CACATGTGTA 60

TTTGTGGGCA 70

26

26



1. An isolated nucleic acid molecule having a nucleic acid sequence encoding a human interleukin-9 receptor variant having one or more variations in the nucleic acid sequence selected from the group consisting of a G to A substitution corresponding to position 1031 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 517-519 of SEQ ID NO: 1, a stop codon at nucleotides corresponding to positions 193-195 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 371-375 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 371-399 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 825-909 of SEQ ID NO: 1, and fragments thereof containing one or more of the variations and encoding a protein capable of binding to IL-9.
2. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 2.
3. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 3.
4. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 5.
5. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 6.
6. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 7.
7. The isolated nucleic acid molecule of claim 1 having the nucleic acid sequence of SEQ ID NO: 4.
8. An isolated DNA molecule having a nucleotide sequence containing the fifth intron of the human IL-9 receptor, wherein the nucleotide corresponding to position 133 of intron five has been changed from T to C.
9. The isolated nucleic acid molecule according to any one of the preceding claims wherein the nucleic acid is DNA.
10. The isolated nucleic acid molecule according to any one of claims 1 to 8 wherein the nucleic acid is RNA.
11. An isolated protein molecule having an amino acid sequence encoding a human interleukin-9 receptor variant having one or more variations selected from the group consisting of a sequence containing a histidine at position 344 corresponding to SEQ ID NO: 27, a sequence wherein glutamine corresponding to amino acid 173 of SEQ ID NO: 27 has been deleted, a sequence wherein the molecule is terminated after amino acid 64 corresponding to SEQ ID NO: 27, a sequence wherein the molecule is



encoded by the nucleic acid molecule of any one of claims 5, 6, 7, and fragments thereof containing one or more of the variations and capable of binding to IL-9.

12. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 28.
13. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 29.
14. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 30.
15. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 31.
16. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 32.
17. The isolated protein molecule of claim 11 having the amino acid sequence of SEQ ID NO: 33.
18. A method for detecting or diagnosing susceptibility to asthma or a related disorder in a human subject comprising determining the presence or absence of the nucleic acid molecule of any one of claims 2 to 7 wherein the presence of only said nucleic acid molecule indicates greater susceptibility to asthma or related disorders.
19. A method for detecting or diagnosing susceptibility to asthma or a related disorder in a human subject comprising determining the presence or absence of the nucleic acid molecule of claim 8 wherein the presence of only said nucleic acid molecule indicates greater susceptibility to asthma or related disorders.
20. An isolated nucleic acid molecule encoding any one of the proteins of claims 11 to 17.
21. A method of alleviating asthma and asthma related disorders by administering to patients in need of such treatment an effective amount of the protein molecule of claim 11.
22. A method of alleviating asthma and asthma related disorders by administering to patients in need of such treatment an effective amount of the protein molecule of any one of claims 12 to 17.
23. Use of an effective amount of the protein molecule of claim 11 for the preparation of a medicament for the alleviation of asthma and asthma related disorders.



24. Use of an effective amount of the protein molecule of any one of claims 12 to 17 for the preparation of a medicament for the alleviation of asthma and asthma related disorders.


Dated this 15th day of February 2002

Magainin Pharmaceuticals Inc.
Patent Attorneys for the Applicant:

F B RICE & CO



Human IL-9 Receptor cDNA



1/18

Fig 1

Sequence Range: 243 to 1944

```

250      260      270      280      290      300      310      320      330      340      350      360      370      380
ATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTACACAG GGAAGGACAA GGGCCAAAGT CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC
H G T W L L A C I C I C T C V C L C V S V T G E G O G P R S R T F T C L T N N I L R I D C H>

390      400      410      420      430      440      450      460      470      480      490      500      510      520
TGGTCTGCC CAGAGCTGGG ACAGGGCTCC AGCCCTCTGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCGAGT AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC
W S A P E L G O G S S P W L L P T S H Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>

530      540      550      560      570      580      590      600      610      620      630      640      650      660
ATCTGACAA TTCACCATCA CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC CCCGGAGACA CGTTAAGCTG GATCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC
S D N P T I T F H H C H S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>

670      680      690      700      710      720      730      740      750      760      770      780      790      800
ACTGCATCT GACCTGGAGC ATCAGTCTCT CTTTGGAGCC AATGACCACA CTTCTCAGCT ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGGCCAGCAC AGGGATCACA TTGTGGGGT GACCTGGCTT
H C I L T W S I S P A L E P H T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>

810      820      830      840      850      860      870      880      890      900      910      920      930      940
ATACTTGAAG CTTTGGAGCT GGACCTCTGC TTTATCCATC AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAG GAGGACCGTT ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT
I L E A F E L D P G F I H E A R L R V Q H A T L E D D V V E E E R Y T G Q W S E W S Q P V C F>

950      960      970      980      990      1000      1010      1020      1030      1040      1050      1060      1070      1080
CCAGGCTCCC CAGAGACAAG GCCCTCTGAT CCCACCTGG GGTGGCCAG GCAACACCCT TGTGTCTGTG TCCATCTTTC TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTG AAGAGAATCT
Q A P Q R Q G P L I P P W G W P G N T L V A V S I F L L L T G P T Y L L F K L S P R V K R I>

1090      1100      1110      1120      1130      1140      1150      1160      1170      1180      1190      1200      1210      1220
TCTACCAGAA CGTGCCTCTT CCAGCGATGT TCTTCCAGCC CCTCTACAGT GTACACAATG GGAATCTCCA CACTTGGATG GGGGCCACCA GGGCCGGTGT GCTGTGAGC CAGGACTGTG CTGGCACCCC ACAGGGAGCC
F Y Q N V P S P A H F F Q P L Y S V H N G N F Q T W H G A H R A G V L L S Q D C A G T P Q G A>

1230      1240      1250      1260      1270      1280      1290      1300      1310      1320      1330      1340      1350      1360
TTGAGGCCCT GCGTCCAGGA GGCCACTGCA CTGCTCACTT GTGGCCACGC GCGTCTTGG AAATCTGTGG CCCTGGAGGA GGAACAGGAG GGCCCTGGGA CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTGCTGCC
L E P C V Q E A T A L L T C G P A R P W K S V A L E E E Q E G P G T R L P G N L S S E D V L P>

1370      1380      1390      1400      1410      1420      1430      1440      1450      1460      1470      1480      1490      1500
AGCAGGGTGT ACGGAGTGGG GGTACAGAC GCTTGCCTAT CTGCCACAGG AGGACTGGGC CCCACCTGCC CTGACTAGGC CGGCTCCCCC AGACTCAGC GGCAGCAGGA GCAGCAGCAG CAGCAGCAGC AGCAACAACA
A G C T E H R V Q T L A Y L P Q E D W A P T S L T R P A P P D S E G S R S S S S S S S S N N>

1510      1520      1530      1540      1550      1560      1570      1580      1590      1600      1610      1620      1630      1640
ACAATACTG TGCCTTGGGC TGTATGGGG GATGGCACCT CTCAGCCCTC CCAGGAACA CACAGAGCTC TGGGCCATC CCAGCCCTGG CCTGTGGCTT TCTTGTGAC CATCAGGGCC TGGAGACCCA GCAAGGAGTT
H N Y C A L G C Y G G W H L S A L P G N T Q S S G P I P A L A C G L S C D H Q G L E T Q Q G V>

1650      1660      1670      1680      1690      1700      1710      1720      1730      1740      1750      1760      1770      1780
GCCTGGGTGC TGGCTGGTCA CTGCCAGAGG CCTGGGCTGC ATGAGGACCT CCAGGGCATG TTGCTCCCTT CTGTCTCAG CAAGGCTCGG TCCTGGACAT TCTAGGTCCC TGACTGCCCA GATGCATCAT GTCCATTTC
A W V L A G H C Q R P G L H E D L Q G H L L P S V L S K A R S W T F V P D S P D A S C P F W>

1790      1800      1810      1820      1830      1840      1850      1860      1870      1880      1890      1900      1910      1920
GGAAAATGGA CTGAAGTTTC TGGAGCCCTT CTCTGAGACT GAACCTCTGT AGAAGGGGCC CCTAGCAGCG GTCAGAGGTC CTGTCTGGAT GGAGGCTGGA GGCTCCCCC TCAACCCCTC TGCTCAGTGC CTGTGGGGAG
E N G L K F L E P L S E T E P P E K G P L A A V R G P V W H E A G G S P L N P S A Q C L W G>

1930      1940
CAGCCTCTAC CCTCAGCATC CTGG
A A S T L S I L>

```

Figure 2

Sequence Range: 243 to 1947

250 260 270 280 290 300 310 320 330 340 350 360 370 380
ATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTACACAGG GGAAGGACAA GGGCCAAAGT CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC
H G T H L L A C I C T C V C L G V S V T G E G Q G P R S R T F T C L T H N I L R I D C H>

390 400 410 420 430 440 450 460 470 480 490 500 510 520
TGCTCTGCC CAGAGCTGG ACAGGGCTCC AGCCCCCTGG TCCTCTTCAC CAGCAACAG GCTCCTGCG GCACACATAA CTGCATCTTG CCGGGCAGTG AGTGCACCGT CGTGTGCGCA CCTGAGGCAG TGCTCTGCGC
H S A P E L G Q G S S P H L L P T S N Q A P G C T H K C I L R G S E C T V V L P P E A V L V P>

530 540 550 560 570 580 590 600 610 620 630 640 650 660
ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTGAGCCT GGTGGACCCG GAGTACCTGC CCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGCGC
S D H F T I T P H H C H S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>

670 680 690 700 710 720 730 740 750 760 770 780 790 800
ACTGCATCCT GACCTGGAGC ATCAGTCTCT CTTTGGAGCC AATGACCACA CTTCTCAGCT ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCGGGGAGCA GGGCCAGCAC AGGGATCACA TTCTCGGGT GACCTGGCCT
H C I L T W S I S P A L E P H T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>

810 820 830 840 850 860 870 880 890 900 910 920 930 940
ATACTGAAG CCTTTGAGCT GCACCTGGC TTTATCCATG AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAG GAGGAGCGTT ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT
I L E A F E L D P G F I H E A R L R V S Q M A T P L E D D V V E E E R Y T G Q W S E W S Q P V C P>

950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
CCAGGCTCCC CAGAGACAAG GCCCTCTGAT CCCACCTGG GGGTGGCCAG GCAACACCTT TGTGTCTGTG TCCATCTTTC TCCTGTCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTG AAGAGAATCT
Q A P Q R Q G P L I P P W G W P G N T L V A V S I F L L L T G P T Y L L P K L S P R V K R I>

1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210 1220
TCTACAGAA CGTCCCTCTT CCAGCGATGT TCTTCCAGCC CCTCTACAGT GTACACAATG GGAACCTTCCA GACTTGGATG GGGGCCACCA GGGCCGGTGT GCTGTGAGC CAGGACTGTG CTGGCACCCC ACAGGGAGCC
F Y Q H V P S P A H P P Q P L Y S V H N G N F Q T W H G A H R A G V L L S Q D C A G T P Q G A>

1230 1240 1250 1260 1270 1280 1290 1300 1310 1320 1330 1340 1350 1360
TTGAGCCCT GCGTCCAGGA GGCCACTGCA CTGCTCACTT GTGGCCAGC GCATCCTTGG AATCTGTGG CCTGGAGGA GCAACAGGAG GGGCCCTGGA CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTCTGCC
L E P C V Q E A T A L L T C G P A H P W K S V A L E E E Q E G P G T R L P G N L S S E D V L P>

1370 1380 1390 1400 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
AGCAGGGTGT ACGGAGTGA GGGTACAGAC GCTTGCTTAT CTGCCACAGG AGGACTGGGC CCCCACCTCC CTGACTAGCC CGGCTCCCCC AGACTCAGAG GGCAGCAGGA GCAGCAGCAG CAGCAGCAGC AGCAGCAACA
A G C T E W R V Q T L A Y L P Q E D W A P T S L T R P A P P D S E C S R S S S S S S S N>

1510 1520 1530 1540 1550 1560 1570 1580 1590 1600 1610 1620 1630 1640
ACAACAATA CTGTGCCCTG GGCTGCTATG GGGATGGCA CCTCTCAGCC CTCCCAGGAA ACACACAGAG CTCTGGGCCC ATCCCAGCCC TGGCTGTGG CTTTCTTGT GACCATCAGG GCCTGGAGAC CCAGCAAGGA
N N N Y C A L G C Y G G W H L S A L P G N T Q S S G P I P A L A C G L S C D H Q G L E T Q Q G>

1650 1660 1670 1680 1690 1700 1710 1720 1730 1740 1750 1760 1770 1780
GTTGCCCTGG TGCTGGCTGG TCACTGCCAG AGGCCTGGGC TGCATGAGGA CCTCCAGGCC ATGTTGCTCC CTTCTGTCTC CAGCAAGGCT CGGTCTGGA CATTCTAGGT CCCTGACTCG CCAGATGCAT CATGTCCATT
V A W V L A G H C Q R P G L H E D L Q G M L L P S V L S X A R S W T P V P D S P D A S C P F>

1790 1800 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900 1910 1920
TTGGGAAAAT GGACTGAAGT TTCTGGAGCC CTTGTCTGAG ACTGAACCTC CTGAGAAGGG GCCCCTAGCA GCGGTACAGG GTCTGTCTG GATGGAGGCT GGAGGCTCCC CCTCAACCC CTCTGCTCAG TGCCTGTGGG
H E N G L K F L E P L S E T E P P E K G P L A A V R C P V W H E A G G S P L N P S A Q C L W>

1930 1940
GAGCAGCCTC TACCCTCAGC ATCCTGG
G A A S T L S I L>

Figure 3

WO 98/24904

3/18

PCT/US97/21992

Friday, November 22, 1996 3:00 PM

Sequence Range: 243 to 1103

```
250      260      270      280      290      300      310      320      330      340      350      360      370      380
ATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC
H G T W L L A C I C I C T C V C L G V S V T G E G Q G P R S R T P T C L T N N I L R I D C H>

390      400      410      420      430      440      450      460      470      480      490      500      510      520
TGCTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCTCTGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTCCC
W S A P E L G Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>

530      540      550      560      570      580      590      600      610      620      630      640      650      660
ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCCTGCC
S D N F T I T P H H C H S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>

670      680      690      700      710      720      730      740      750      760      770      780      790      800
ACTGCATCCT GACCTGGAGC ATCAGTCTTG CCTTGGAGCC AATGACCACA CTTCTCAGCT ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGGCCAGCAC AGGGATCACA TTGTCGGGGT GACCTGGCCT
H C I L T W S I S P A L E P M T T L L S Y E L A F K K Q E E A H E Q A Q H R D H I V G V T W L>

810      820      830      840      850      860      870      880      890      900      910      920      930      940
ATACTTGAAG CCTTTGAGCT GGACCCTGGC TTTATCCATG AGGCCAGCCT GCGTGTCCAG ATGGCCACAC TGGAGGATCA TGTGCTAGAG GAGGAGCGTT ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTCTTT
I L E A F E L D P G F I H E A R L R V Q M A T L E D D V V E E E R Y T G Q W S E W S Q P V C F>

950      960      970      980      990      1000      1010      1020      1030      1040      1050      1060      1070      1080
CCAGGCTCCC CAGAGACAAG GCCCTCTGAT CCCACCCTGG GGGTGGCCAG GCAACACCCT TGTTCCTCTG TCCATCTTTC TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGACTT CGATGGGGGC
Q A P Q R Q G P L I P P W G H P G N T L V A V S I F L L L T G P T Y L L F K L S P R L G H G>

1090      1100
CCACAGGGCC GGTGTGCTGT TGA
P T G P V C C *>
```

Sequence Range: 242 to 1944

```

    250      260      270      280      290      300      310      320      330      340      350      360      370      380
ATGGGCGAC CTGGCTCCTG GCGTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTACACAG GGAAGGACAA GGCCCAAGGT CTAGAACCCT CACCTGCCCT ACCACACAAC TTCTCAGGAT CGATTGCCAC
M G T W L L A C I C I C T C V C L G V S V T G E C Q G P R S R T F T C L T N N I L R I D C H>

    390      400      410      420      430      440      450      460      470      480      490      500      510      520
TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCTTGGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG AGTGCACCGT CGTGTCTCCA CCTCAGGCAG TGCTCGTCCC
W S A P E L Q Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>

    530      540      550      560      570      580      590      600      610      620      630      640      650      660
ATCTGACAAT TTCACCATCA CTTCACCACT CTGCATGTCT GGGAGGGAGC AGCTCAGCCT GGTGGACCCG GAGTACCTGC CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCCTGGC
S D H F T I T P N H C H S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>

    670      680      690      700      710      720      730      740      750      760      770      780      790      800
ACTGCATCCT GACCTGGAGC ATCAGTCTCT CGTTGGAGCC AATCACCACA CTCTCAGCT ATGAGGTGCC CTTCAGAAG CAGGAACAGG CCTGGGAGGC CCAGCAGCAG GATCAGATG TCGGGGTGAC CTGGCTTATA
H C I L T W S I S P A L E P H T T L L S Y E L A F K K Q E E A W E A Q H R D H I V G V T W L I>

    810      820      830      840      850      860      870      880      890      900      910      920      930      940
CTTGAAGCCT TTGAGCTGGA CCCTGGCTTT ATCCATGAGG CCAGGCTGCC TGTCAGATG GCCACACTGG AGGATGATGT GGTAGAGGAG GAGCGTTATA CAGGCCAGTG GAGTGAAGTG AGCCAGCCTG TGTGCTTCCA
L E A F E L D P G F I H E A R L R V Q H A T L E D D V V E E E R Y T G Q N S E H S Q P V C F Q>

    950      960      970      980      990      1000      1010      1020      1030      1040      1050      1060      1070      1080
GGTCCCCAG AGACAAGGCC CTCTGATCCC ACCCTGGGGG TGGCCAGGCA ACACCTTGT TGTGTGTGCC ATCTTTCTCC TGCTGACTGG CCCGACCTAC CTCCTGTICA AGCTGTGCC CAGCGTGAAG AGAATCTTCT
A P Q R Q G P L I P P W G W P G H T L V A V S I F L L L T G P T Y L L F K L S P R V K R I F>

    1090      1100      1110      1120      1130      1140      1150      1160      1170      1180      1190      1200      1210      1220
ACCAGAAGCT GCCCTCTCCA GCGATGTCT TCCAGCCCTC CTACAGTCTA CACATCGGA ACTTCAGAC TTGGATGGGG GCCCACAGGG CCGGTGTGCT GTTGAGCCAG GACTGTGCTG GCACCCACCA GGGAGCCTTG
Y Q N V P S P A H F P Q P L Y S V H N G N F Q T W H G A H R A G V L L S Q D C A G T P Q G A L>

    1230      1240      1250      1260      1270      1280      1290      1300      1310      1320      1330      1340      1350      1360
GAGCCCTGCC TCCAGGAGGC CACTGCAGTG CTCACITGTG GCCCAGCGCG TCCTTGGAAA TCTGTGGGCC TGGAGGAGGA ACAGGAGGGC CCTGGGACCA GGCTCCCGGG GAACCTGAGC TCAGAGGATG TGCTGCCAGC
E P C V Q E A T A L L T C G P A R P H K S V A L E E E Q E G P G T R L P G H L S S E D V L P A>

    1370      1380      1390      1400      1410      1420      1430      1440      1450      1460      1470      1480      1490      1500
AGGGTGTACG GAGTGGAGGG TACAGACGCT TGCCTATCTG CCACAGGAGG ACTGCCCCCG CACGTCCCTG ACTAGGCCGG CTCGCCACGA CTCAGAGGGC AGCAGGACCA GCAGCAGCAG CAGCAGCAGC AGCAACAACA
G C T E W R V Q T L A Y L P Q C D W A P T S L T N P A P P D S E G S H S S S S S S S S N N>

    1510      1520      1530      1540      1550      1560      1570      1580      1590      1600      1610      1620      1630      1640
ACAATCTACT TGCTTTGGCG TGCTATGGGG CATGGCACCT CTCAGCCCTC CCAGGAACA CACAGAGCTC TGGGCCCATC CCAGCCCTGG CCTGTGGCCT TTCTTGTGAC CATCAGGGGC TGGACACCCA CCAAGGAGTT
N N Y C A L G C Y G G W H L S A L P G H T Q S S G P I P A L A C G L S C D H Q G L E T Q Q G V>

    1650      1660      1670      1680      1690      1700      1710      1720      1730      1740      1750      1760      1770      1780
GGCTGGGTGC TGGCTGGTCA CTGCCAGAGG CCTGGGCTGC ATGAGGACCT CCAGGGCATG TTGCTCCCTT CTGTCTCAG CAAGGCTCGG TCCTGGACAT TCTAGGTCCC TGACTGCCCA GATGCATCAT GTCCATTTC
A W V L A G H C Q R P G L H E D L O G H L L P S V L S K A R S W T F V P D S P D A S C P P W>

    1790      1800      1810      1820      1830      1840      1850      1860      1870      1880      1890      1900      1910      1920
CGAAATGCA CTGAAGTTTC TGCAGCCCTT GTCTCAGACT GAACCTCCTC AGAAGGGGCC CCTAGCAGCG GTACAGGCTC CTCTCTGCAT CGAGGCTGGA GGCTCCCCCG TCAACCCCTC TGCTCACTGC CTGTGGGAG
E N G L K F L E P L S E T E P P E K G P L A A V R G P V H H E A G G S P L N P S A Q C L W G>

    1930      1940
CAGCCTCTAC CCTCAGCATC CTGG
A A S T L S I L>

```

Figure 5

210 220 230 240 250 260 270 280 290 300 310 320 330
GCT GGACCTTGA GAGTGAGGCC CTGAGGCGAG ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTCACAGG GGAAGGACAA GGGCCAAGGT
M G T W L L A C I C I C T C V C L Q V S V T G E G Q G P R>
340 350 360 370 380 390 400 410 420 430 440 450 460
CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCAACATAA
S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
470 480 490 500 510 520 530 540 550 560 570 580 590
GTGCATCTTG CGGGGAGTG AGTGCACCGT QGTGCTGACA CCTGAGGCAG TGCTCGTGCC ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCC? GGTGGACCCG
C I L R G S E C T V V L P P E A V L V P S D N P T I T F H H C M S G R E Q V S L V D P>
600 610 620 630 640 650 660 670 680 690 700 710 720
GAGTACCTGC CCQGGAGACA CGCTGGACCC GCCCTCTGAC TTGCAGAGCA ACATCAGTTC TGGCCACTGC ATCCTGACCT QGAGCATCAG TCCTGCCTTG GAQCCAATGA CCACACTTCT CAGGTATGAG
E Y L P R R H A G P A L>

Figure 6

210 220 230 240 250 260 270 280 290 300 310 320 330
GCT GGACCTTGA GAGTGAGGCC CTGAGGCGAG ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTCACAGG GGAAGGACAA GGGCCAAGGT
M G T W L L A C I C I C T C V C L G V S V T G E G Q G P R>
340 350 360 370 380 390 400 410 420 430 440 450 460
CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA
S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
470 480 490 500 510 520 530 540 550 560 570 580 590
GTGCATCTTG CGGGGCAGTG AGTGCACCGT COTGCTGCCA CTTGAGGCAG TGCTCQTGCC ATCTGACAAT TTCACCATCA CTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG
C I L R G S E C T V V L P P E A V L V P S D N F T I T F H H C M S G R E Q V S L V D P>
600 610 620 630 640 650 660 670 680 690 700 710 720
GAGTACCTGC CCCGGAGACA CGAGCAACAT CAGTTCTGGC CACTGCATCC TGACCTGGAG CATCAQTCT GCCTTGGAGC CAATGACCAC ACTTCTCAGC TATGAGCTGG CCTTCAAGAA GCAGGAAGAG
E Y L P R R H E Q H Q F W P L H P D L E H Q S C L G A N D H T S Q L>

Figure 7

EX4-DEL Translated Sequence
Friday, November 22, 1996 3:01 PM

Sequence Range: 243 to 437

```
      250      260      270      280      290      300      310      320      330      340      350      360      370      380
      .      .      .      .      .      .      .      .      .      .      .      .      .      .
ATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTCACAGG GGAAGGACAA GGGCCAAAGT CTAGAAGCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGCCAC
H G T W L L A C I C I C T C V C L G V S V T G E G Q G P R S R T P T C L T N N I L R I D C H>

      390      400      410      420      430
      .      .      .      .      .
TGCTCTGCC CAGAGCTGGG ACAGGGCTCC AGCCCTGGC TCCTCTTCAC CAGTTAA
W S A P E L G Q G S S P W L L F T S *>
```

Interleukin-9 Receptor Variants

<u>Phenotype</u>	<u>Genotype</u>		
	Arg/Arg	Arg/His	His/His
allergic	1/18	8/18*	1/18*
nonallergic	7/18	1/18	0/18
Fisher Exact Test P = 0.002**			

* includes asthmatics

** assumes allergy is autosomal dominant trait

FIGURE 9

Comments for pCEP4:

10380 base pairs

SV40 Poly A signal: bases 7-405

Multiple Cloning Site: bases 406-463

CMV Promotor: bases 467-1311

TK Poly A signal: bases 1473-1843

Hygromycin gene: bases 1844-2893

TK Promotor: bases 2894-3136

Ampicillin resistance/pUC origin: bases 3635-5526

EBNA-1 gene: bases 5593-8113

OIP: bases 8142-10078




Figure 10




Figure 11




Figure 12





FIGURE 13





Fig 14 Panel A

~~B~~



file 14 PANEL B

~~A~~








Fig 15

Fig 16



Intron 5 Polymorphism of the human IL-9 Receptor

WT human IL-9 Receptor Sequence						
90	100	110	120	130	↓ 140	150
AAAGTGTGATG	AGTGTGAAG	TGTTCCCTGTA	GACATGCTTTC	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA>
AAAGTGTGATG	AGTGTGAAG	TGTTCCCTGTA	GACATGCTTTC	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA

Mutant IL-9 Receptor Sequence						
90	100	110	120	130	↓ 140	150
AAAGTGTGATG	AGTGTGAAG	TGTTCCCTGTA	GCATGCTTTC	CCTGTGTGTG	CACATGTGTA	TTTGTGGGCA>
AAAGTGTGATG	AGTGTGAAG	TGTTCCCTGTA	GACATGCTTTC	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA

Figure 17